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 In the last decade, galectin-3 has emerged as an important player in the 
development and progression of cancer, favoring immune suppression and 
dysfunction at disease sites. While this protein is a known tumor-promoting factor, its 
unique properties make the mechanisms of its functions difficult to study, and impede 
the development of therapies against it. Galectin-3 recognizes and binds b-
galactoside carbohydrate residues through a highly-conserved C-terminal domain 
(CRD). It uniquely self-associates into homo-oligomers through a disordered N-
terminal domain (NTD). We have previously shown that immune responses against 
galectin-3 are protective in pancreatic ductal adenocarcinoma (PDAC), and that its 
knockout in a mouse model of tumor tolerance improves effector function of antitumor 
CD8+ T cells and increases duration of tumor-free survival, suggesting a suppressive 
role for galectin-3 in antitumor immunity. The mechanisms of this suppression remain 
unknown.  
 To learn whether galectin-3 could be a target for preventative therapeutics, I 
examined disease progression in a genetically engineered mouse model of PDAC 
development upon abrogation of galectin-3. I saw no significant change in lesion 
development or overall survival, indicating that galectin-3 is unlikely to be a good 
target for prevention strategies. In an effort to further study its mechanisms of immune 
suppression, I developed an assay to model galectin-3-mediated CD8+ T cell 
suppression, and showed that this assay allows successful activation of antigen-
specific CD8+ T cells in vivo and detection of effector cytokines after re-stimulation in 
vitro. Through this assay we expect to learn how the discrete galectin-3 binding 
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domains each impact its suppressive functions. Finally, I examined a transgenic 
mouse strain with a deficiency in dendritic cell populations, which regains those 
populations upon abrogation of galectin-3. This puzzling phenomenon remains 
unsolved, but I posit some lines of future inquiry that could elucidate this phenomenon, 
and inform our studies of galectin-3-mediated T cell modulation as well. 
 Galectin-3 has been known as a factor in tumor permissiveness for decades, 
but has not yet been effectively targeted. Determining the mechanisms behind 
galectin-3-mediated immune cell modulation in the context of tumor will allow it to be 
targeted effectively, and could lead to better immunotherapeutic outcomes. 
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CHAPTER 1: Introduction 
 
Galectin-3: A Multifunctional Modulator of Inflammation, Motility, and Immunity 
In recent years, cancer immunotherapy has dramatically altered the landscape 
of cancer treatment, both in accompaniment with and as an alternative to conventional 
chemoradiotherapy (1). Immunotherapy, however, remains an imperfect solution due 
to our incomplete understanding of the factors that work alongside cancerous cells to 
suppress and silence the antitumor functions of the immune system, and evasion of 
antitumor immunity is now considered a hallmark of cancer (2). It is therefore important 
not only to research new immunotherapeutic approaches, but also to further our 
understanding of the factors that can contribute to the failure of these treatments in 
certain patient populations. Extensive study has shown the protein galectin-3 to be 
capable of promoting tumor growth, invasion, and metastasis, while also contributing 
to adaptive immune suppression in a tumor context (3,4).  
 Galectin-3 is a 31kD b-galactoside-binding protein, unique in structure among 
galectin family members for its N-terminal disordered tail domain (NTD), and C-
terminal carbohydrate recognition domain (CRD) typical of mammalian galectins (5,6). 
It is ubiquitously produced and can exert functions both intracellularly and 
extracellularly (7), but is most studied in disease contexts, where it generally takes 
part in dysfunctional regulation. In the cytosol, galectin-3 is known as a binding partner 
of apoptotic regulators such as B-cell lymphoma 2 (BCL2), CD95 (APO-1/Fas), and 
Nucling (8–10), and also regulates cell proliferation, differentiation, and survival 
through interactions with Ras proteins and Akt (11,12). At the cell surface, galectin-3 
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canonically binds N-acetyllactosamine repeats in the branched N- and O-linked 
oligosaccharides of the glycocalyx (13,14). These binding events are understood to 
occur through the CRD, while the NTD has been understood to allow oligomerization 
of galectin-3 molecules (3,15). More recently, it has been shown that intermolecular 
interactions between galectin-3 proteins may also occur through CRD-CRD or NTD-
CRD interactions (16). These oligomerization events lead to the formation of 
multivalent assemblies of galectin-3 and lattice formation upon binding of its 
extracellular glycan ligands. Such lattices may influence the signaling downstream of 
affected surface proteins which carry the target glycan residues by causing clustering 
that can impede or enhance signal transduction into the cell (17). Multivalent galectin-
3 oligomers also influence the ability of cells to interact with the extracellular matrix 
(ECM) and migrate to distal sites (4,18,19). These diverse functions are often found 
to be immune modulatory, as galectin-3 is known to play roles specifically in the 
contexts of tumor, autoimmune disease, and tissue damage and repair (7). 
 
Antitumor Immune Functions of CD8+ T cells and Antigen-Presenting Dendritic 
Cells 
 The last fifteen years have brought a new appreciation of how crucial immune 
cell function is for the control and rejection of tumors. Our new understanding of how 
immune cell functions are subverted by tumor cells for eventual immune evasion and 
escape has given rise to immunotherapy, a set of treatments that aim to restore 
immune cell effector functions while removing the brakes from immune regulation (1). 
Two cell types which play key roles in tumor control are cytotoxic CD8+ T cells and 
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dendritic cells (DCs), and both have arisen in our research as cell types which may 
interplay with galectin-3 in the tumor microenvironment (20). 
 CD8+ T cells are potent killers of tumor cells, but can also be silenced upon 
entry into the tumor microenvironment (21). They respond best to tumors with a high 
mutational burden, which are more likely to produce antigens these T cells can 
recognize (22,23). Naïve CD8+ T cells become activated upon meeting their cognate 
antigen presented on antigen-presenting cells (APCs) bearing the class I major 
histocompatibility complex (MHC class I) in the lymph node, undergo activation, and 
can then traffic to the tumor site and perform killing functions against cells bearing 
tumor antigens through the release of inflammatory cytokines and cytotoxic granules 
(24).  
The surface receptors that normally function to dampen the cytotoxicity of CD8+ 
T cells by preventing damage associated with an overactive immune response can 
also be co-opted by tumors to evade killing. The best-studied surface receptor that 
mediates such interactions is PD-1 (CD279), which is now known as a checkpoint 
molecule due to its well-documented CD8+ T cell inhibition. PD-1 on the T cell binds 
to a ligand, usually PD-L1 (B7-H1, CD274) or PD-L2 (B7-DC, CD273) (25). In the 
context of cancer, tumor cells can express these ligands, transducing inhibitory signals 
into the cytotoxic T cell and preventing further instances of killing. PD-1 is now the 
target of immune checkpoint antibody blockade strategies, which are promising 
components of immunotherapy. However, despite these new therapies, other factors 
beyond canonical checkpoint molecules continue to interfere with CD8+ T cell effector 
function in the context of tumor. 
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Dendritic cells (DCs) are professional antigen-presenting cells (APCs), and 
drive adaptive immune responses by priming naïve CD4+ and CD8+ T cells (26). There 
are many distinct DC subsets, but most are primarily identified by expression of the 
surface marker CD11c (27). In their role as presenters of antigen both in secondary 
lymphoid organs and at the tumor site, they have arisen as a critically important arm 
of the antitumor immune response (28). Their cross-presentation of tumor associated 
antigens on MHC class I is a cornerstone of the CD8+ T cell antitumor response, and 
is necessary both to prime naïve CD8+ T cells and to drive their cytotoxic function at 
the tumor site (29). Defects in antigen cross-presentation are common dysfunctions 
of DCs in the tumor context (30–32), and these remain some of the less-studied 
components that can disrupt current immunotherapeutic approaches. Galectin-3 has 
been implicated in processes that target both of these crucial cell types, forming the 
impetus behind my studies of this protein. 
 
Galectin-3 in Immune Suppression and Tumor Promotion 
 Galectin-3 is one of the major factors that leads to the dysfunction of antitumor 
immune cells (3). Its functions result in a tumor-promoting microenvironment through 
the effects it has on the tumor cells themselves, on the stromal cells of the 
microenvironment, and on antitumor immune effector cells.  
 The internal and external functions facilitated by galectin-3 on tumor cells are 
directly involved in multiple hallmarks of cancer. It contributes to the transformation of 
tumor cells through interactions with oncogenic Ras proteins, specifically KRAS (33). 
In the cytosol, it can suppress apoptotic signals, due in part to its homology with the 
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protein BCL2, which allows it to traffic to the mitochondria to block apoptosis (34,35). 
Importantly, galectin-3 increases the metastatic potential of tumor cells and promotes 
invasion, metastasis, and colonization of distal sites by mediating cell-cell adhesion 
between tumor cells (4), promoting the epithelial-to-mesenchymal transition (18), and 
facilitating tumor cell interactions with the extracellular matrix (19). It also promotes 
angiogenesis at the tumor site, an important factor for tumor cell survival in hypoxic 
conditions (36). 
 The effects of galectin-3 on CD8+ T cell antitumor functions come from multiple 
angles at once. Galectin-3 can decrease the affinity of the T-cell receptor (TCR) for 
MHC class I-antigen complexes by forming galectin-3-TCR lattices, sequestering 
TCRs from their co-receptor CD8 (37). Other studies have shown that galectin-3 can 
induce CD8+ T cell apoptosis through interactions with CD29 and CD7 (38). Our lab 
has shown that galectin-3 binds the suppressive signaling molecule LAG-3, and 
proposed that such binding could cluster surface LAG-3 and induce suppressive 
signals that dampen CD8+ T cell antitumor effector functions at the tumor site (20).  
 
Overview of Thesis Work 
 The overall goal of this thesis is to use a mouse model of cancer development 
to learn more about whether galectin-3 would be a viable target for preventative 
therapies, and to develop methods that allow us to determine the mechanisms by 
which galectin-3 suppresses antitumor CD8+ T cells. This has been accomplished by: 
1. Comparing pancreatic lesion development and overall survival in a 
genetically-engineered mouse model of pancreatic ductal adenocarcinoma 
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(PDAC) to age- and sex-matched mice with a genetic ablation of galectin-
3, showing that removal of galectin-3 does not significantly impact temporal 
progression through the stages of PDAC development or survival at any 
time point. 
2. Attempting the development of a new in vitro assay for the identification of 
putative galectin-3 binding partners on the CD8+ T cell surface. 
3. Developing an in vitro assay to assess the ability of galectin-3 to suppress 
in vivo-activated CD8+ T cells upon re-stimulation, and using mutant 
galectin-3 proteins with loss of function of one or more galectin-3 binding 
domain to determine how these domains each impact suppressive 
potential. 
4. Exploring the link between galectin-3 and dendritic cell subsets in a tumor-




CHAPTER 2: Effect of Galectin-3 Abrogation in a Mouse Model of Pancreatic 
Ductal Adenocarcinoma (PDAC) Development 
 
Rationale and Experimental Design 
 Pancreatic ductal adenocarcinoma (PDAC) is currently one of the deadliest 
cancers, and one of the least likely to be detected before metastases develop and 
worsen disease outcomes (39). Additionally, PDAC is often poorly infiltrated by 
antitumor immune cells, which can make immunotherapies a less effective treatment 
strategy (40). Our lab works extensively on determining how the components of the 
PDAC tumor microenvironment contribute to tumor-permissiveness, and how these 
components can be perturbed to make inroads for immunotherapy and influence 
better treatment outcomes for patients.  In a previous study of PDAC patients receiving 
two whole-cell GM-CSF-secreting pancreatic tumor cell lines as vaccine, our lab 
showed that an elevated level of serum anti-galectin-3 IgG was found to be correlated 
with improved disease outcome (disease-free survival >3 yrs) (20).  67% of patients 
who survived longer than three years post-treatment showed twofold or higher 
increase of anti-galectin-3 antibody titers, while only 9.5% of patients who survived 
less than three years showed a similar increase. Additionally, sera taken from these 
good-responder patients were capable of inhibiting galectin-3-mediated suppression 
of healthy donor CD8+ T cells in vitro (20). Galectin-3 has already been described as 
a promoter of a tumor-permissive immune microenvironment as detailed in Chapter 
1, and the data from our lab indicate that it may play such a role in PDAC specifically.
  To begin such study, we wanted to discover the effect of galectin-3 abrogation 
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on pancreatic lesion development and overall survival in a mouse model of PDAC 
development and progression. The mouse strain LSL-KrasG12D/+;LSL-
Trp53R172H/+;Pdx-1-Cre (KPC) has been shown through histological and survival 
assessment to model the development and progression of human PDAC in a temporal 
manner (41). These mice carry an activated oncogenic Kras mutation as well as a 
dominant negative allele of the p53 tumor suppressor, both under the control of Pdx-
1-Cre, driving expression specifically in pancreatic tissues (42). Mice develop low-
grade pancreatic intraepithelial neoplasms (PanINs) between 4-6 weeks of age, with 
high-grade PanINs detectable at 8-10 weeks. By about 12 weeks of age, most KPC 
mice have begun to progress from PanINs to PDAC. Our lab has utilized the KPC 
mouse model to study the efficacy of tumor vaccines and immune modulators in 
preventing or slowing the development of PanINs and PDAC (43). To discover the 
effect of galectin-3 abrogation on this model, we crossed the parental strains of the 
KPC mouse model to matched-background Lgals3-/- (galectin-3 KO) mice, then 
performed assessments of disease progression, immune cell infiltrate, and survival in 
age-matched cohorts of KPC and LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-
Cre;Lgals3-/- (KPC-G) mice. 
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Materials and Methods 
Generation of LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre;Lgals3-/- (KPC-G) 
Mice 
 LSL-KrasG12D/+;LSL-Trp53R172H/+; and Pdx-1-Cre strains on a mixed 
129/SvJae/C57Bl/6 background were a gift from Dr David Tuveson (Cold Spring 
Harbor Laboratory, Cold Spring, NY). These mice were backcrossed to the C57Bl/6 
background for twelve generations as previously described (43). The two parental 
strains (LSL-KrasG12D/+;LSL-Trp53R172H/+ and Pdx-1-Cre) are interbred to obtain 
KPC mice (42). Each of these strains was therefore crossed with Lgals3-/- (galectin-3 
KO) mice of a C57Bl/6 background to achieve galectin-3 homozygous KO animals of 
each parental strain. Genotypes were assessed by taking tail biopsies at 3 weeks of 
age and sending to Transnetyx for analysis with previously-developed genotyping 
protocols and primers. To generate the Pdx-1-Cre, Lgals3-/- mice, zygosity testing for 
Cre was necessary. A protocol for testing was generated under the advice of Charles 
River Laboratories, who processed the samples for zygosity testing. Animals 
homozygous for both Pdx-1-Cre and knockout of galectin-3 were utilized as breeders 
for this parental strain. Upon interbreeding, roughly 25% of progeny were genotyped 
as LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre;Lgals3-/- (KPC-G). Animals were 
housed in the Johns Hopkins Animal Facility and cared for according to protocols 





Histological Assessment of PanIN Lesions of Age-Matched KPC and KPC-G Mice 
 KPC and KPC-G mice were obtained by interbreeding as described previously, 
and genotypes were determined by analysis of tissue samples taken at three weeks 
of age and sent for remote genotyping by Transnetyx. As genotypes were determined, 
KPC and KPC-G progeny were randomized into cohorts on a rolling basis. In total, ten 
male and ten female mice of each genotype (KPC or KPC-G) were enrolled into each 
age group cohort (4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, or 14 weeks). 
Upon reaching the desired age plus or minus two days, mice were sacrificed and 
pancreata harvested. Whole pancreata were fixed by 48 hour incubation in 10% 
formalin, then paraffin-embedded. Two sections were cut from each pancreas, with 
sections sampled 1 mm apart and mounted on the same slide in the same orientation. 
Slides were H&E stained. Histological assessment and PanIN grading was performed 
in conference with clinical pathologists, whereby both sections were examined for the 
presence of PanIN lesions, and/or PDAC. Samples were given scores of No PanIN, 
PanIN 1, PanIN 2, PanIN 3, or PDAC based on published protocols (41,44), and the 
presence or absence of concurrent pancreatitis in each sample was noted. The final 
PanIN grade for each mouse was determined by the highest-grade lesion present 
across two pancreatic sections from the same individual. PanIN scores were grouped 
into No PanIN, Low-Grade (PanIN 1 or 2), and High-Grade (PanIN 3 or PDAC), and 





Immunohistochemical Assessment of KPC and KPC-G Mouse Pancreata 
 New slides were cut from FFPE pancreata of the KPC and KPC-G mice 
previously sectioned for H&E staining and PanIN grading. These slides were stained 
by immunohistochemical protocols developed by Johns Hopkins Oncology Tissue 
Services for the markers CD3 and CD11b to broadly characterize lymphoid and 
myeloid cell infiltrates in and around pancreatic lesions. Assessment of immune cell 
infiltrate was performed by examining slides under 10X and 100X magnification and 
recording qualitative comparisons of cell infiltrates while blinded to the genotype and 
age group of each sample, then un-blinding after assessment of all samples and 
comparing descriptions within groups for similarities and differences. 
 
Survival Comparison of KPC and KPC-G Mice 
 As litters from interbred mice were genotyped, mice identified as KPC or KPC-
G were placed into groups and their survival followed. In total, fifteen male mice and 
fifteen female mice of each genotype (KPC or KPC-G) were followed, for a total of 
thirty mice per genotype. Endpoint of the experiment was defined as either 
spontaneous death, or morbidity requiring sacrifice per animal protocols and 
conferences with veterinary staff. Survival data were graphed and median survival 




Breeding and Housing of KPC-G Mice and Sensitivity to H. pylori 
 Initial attempts to breed KPC-G mice resulted in few to no progeny, and those 
that were born had severe health problems. Infection with Helicobacter pylori (H. 
pylori) of facility-housed mice is a common problem, and while our KPC mice had 
been regularly tested for this and found negative, the researcher who crossed the KPC 
parental strains (LSL-KrasG12D/+;LSL-Trp53R172H/+ and Pdx-1-Cre) to galectin-3 
knockout animals had incurred a contamination during the breeding process. After 
discovering the contamination, we began the process of cross-fostering these parental 
strains to remove the infection. During this process, I found by literature review that 
galectin-3 plays a role in innate immunity against H. pylori, preventing its deep 
infiltration into gut tissue, and causing aggregation that contributes to bacterial killing 
and disease control (45). The cited study showed that galectin-3 knockout animals 
infected with H. pylori were susceptible to significant weight loss and gut inflammation 
compared to wildtype animals, which was congruent with the phenotype of the few 
early KPC-G progeny we observed. Indeed, once the parental strains of the KPC-G 
mice were successfully cross-fostered, they bred robustly and birthed expected 
proportions of KPC-G progeny. It is important, therefore, that all future researchers 
planning to utilize any galectin-3 knockout animals ascertain that they are kept free of 
this pathogen, particularly when utilizing galectin-3 knockout in heavily genetically 




KPC-G Mice Have Delayed Onset of PanIN Lesion Development 
 KPC and KPC-G mice were enrolled into study groups by age on a rolling basis. 
Age groups enrolled were 4, 6, 8, 10, 12, and 14 weeks of age. At target age plus or 
minus two days, mice were sacrificed and whole pancreata fixed and sectioned for 
H&E staining. In conference with clinical pathologists, we scored pancreata by 
determining the highest-grade lesion present in each sample. After determining PanIN 
score for each sample, scores were separated into one of three possible groupings: 
No Disease (No PanIN), Low-Grade Disease (scores of PanIN 1 or PanIN 2), and 
High-Grade Disease (PanIN 3 or PDAC).  
 Both KPC and KPC-G mice are susceptible to the development of PanIN 
lesions, pancreatitis, and PDAC. However, mice in the KPC-G cohorts were more 
likely than their KPC counterparts to remain disease-free for a longer period of time. 
While both groups of 4-week-old mice included individuals at each of the three stages 
of disease progression, certain KPC-G mice remained disease-free longer than their 
KPC counterparts. While 6 weeks of age was the latest KPC time point with disease 
free individuals, disease-free KPC-G mice were sampled at both 8 weeks and 10 
weeks of age (Figure 1). By 12 and 14 weeks of age, however, the KPC and KPC-G 
mice had equal proportions of mice in each disease group, and no individuals 
remaining disease free. Therefore, though PDAC development may have a later onset 





Immune Cell Infiltrate is Dependent on Disease State 
 FFPE pancreata from the PanIN scoring groups were then grouped by disease 
score and inflammation state, and two individuals from each group were chosen for a 
pilot immunohistochemical analysis. Serial sections were cut from each pancreas and 
stained in parallel for CD3 and CD11b, to mark lymphoid and myeloid cell infiltrates, 
respectively. These slides were blinded, then qualitatively analyzed to gauge 
differences in infiltrate between disease scores, inflammation state, and genetics, 
once again comparing KPC to KPC-G animals. Broadly and expectedly, larger myeloid 
infiltrates were seen within known PDAC lesions, while larger lymphoid infiltrates were 
seen in the presence of pancreatitis. These patterns were consistent across KPC and 
KPC-G, and the sample size of each genotype at each stage of disease was too small 
to discern a difference upon galectin-3 abrogation. 
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KPC and KPC-G Mice Have Sex-Specific Survival Benefits 
 To assess survival differences between KPC and KPC-G mice, animals were 
genotyped at three weeks of age, enrolled into either the KPC or KPC-G group 
respectively, and followed to an endpoint of either spontaneous death or morbidity 
requiring euthanasia per research animal protocols. Thirty mice were followed in each 
group, with male and female mice equally represented. At the conclusion of the 
survival experiment we observed interesting phenomena. While all KPC mice (n = 30) 
were deceased before 200 days, twenty percent (n = 6) of KPC-G mice were still living 
(Figure 2A). This difference becomes more stark when mice are analyzed by sex. All 
KPC-G mice that survived to 200 days or beyond were female, and the longest-lived 
survived for 294 days, 100 days longer than the longest-lived KPC mouse (Figure 
2B). Additionally, when median survival of males and females in each group was 
assessed, a survival benefit was seen in KPC female mice as well. This is largely 
attributable to the fact that the KPC female cohort, as a whole, lasted the longest 
before its first individual reached an endpoint. 
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Figure 2: Survival of KPC and KPC-G mice is not significantly impacted by 
galectin-3 abrogation, but is sex-specific. A. The survival comparison between 
KPC and KPC-G mice shows no difference in median survival, but does indicate a 
subset of KPC-G mice that persist longer than other individuals. B. When survival is 
analyzed by sex, it can be seen that all longer-lived KPC-G mice are female. 
Additionally, female KPC mice seem to have a survival benefit apparent in longer 
cohort survival before the first death. While survival differences do not appear to be 
based on loss of galectin-3, the sex-based survival differences observed here should 




 Whether assessing PanIN development or immune cell infiltrate, no statistically 
significant differences were seen in KPC-G mice compared to KPC at baseline. There 
are, however, some differences that may warrant future study, and some pitfalls that 
should be avoided. First, the fact that there were disease-free KPC-G mice sampled 
at 8 and 10 weeks of age is of potential interest. The oldest disease-free KPC mice 
sampled were 6 weeks of age. This could indicate that a subset of KPC-G mice would 
be more sensitive to early treatment protocols. Our lab has previously shown that a 
Listeria monocytogenes vaccine against oncogenic Kras(G12D), along with Treg 
depletion, slows disease progression of KPC mice with low-grade, but not high-grade 
PanINs (43). If KPC-G mice are disposed to remain PanIN and PDAC-free for a longer 
period of time, they may be more likely to respond to such a vaccine protocol. Vaccine 
studies may also help to elucidate the immune mechanism by which galectin-3 
suppresses antitumor responses. Translating the benefits observed in galectin-3 
abrogation clinically is more challenging, as it is a ubiquitous protein with systemic 
effects, but confirming its immune mechanisms of action could elucidate further 
targetable pathways.   
 One major pitfall of my studies of PanIN lesion development and immune cell 
infiltrate is sampling error. In my study of immune cell infiltrate, for instance, too few 
samples were stained from each disease stage and inflammation state to be certain 
that differences in CD3+ or CD11b+ cell numbers were actually due to genotype rather 
than disease progression or the presence of pancreatic inflammation. The only 
notable phenomena seen in this study was CD11b+ cells collecting in and near PDAC 
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tumors, and elevated CD3+ cells in the presence of pancreatitis (data not shown), both 
of which are predictable and well-described in previous studies. Since disease 
outcomes in human PDAC depend on a confluence of these factors, future 
immunohistochemical comparisons of KPC and KPC-G mice should involve samples 
carefully paired based both on PanIN lesion stage and the degree of inflammation 
present, with multiple individual samples per group. 
Additionally, and most critically, when sampling mice to compare PanIN 
lesions, I made the mistake of randomly assigning mice to groups after genotyping, 
and continuing enrollment in each group until the target number of samples was met, 
as defined by live mice sacrificed at the target age. The problem with this approach is 
that it introduces selection bias- for instance, if a mouse is enrolled in the 12 week age 
group, but dies by 8 weeks, the animal should still be considered part of the 12 week 
group, but noted to have met the endpoint before reaching the target age. In nearly 
every case, such animals will be found by necropsy to have high-grade lesions, PDAC, 
and/or severe pancreatitis. Disregarding the enrolled animals that met the endpoint 
before reaching the target age means that the later age groups were biased toward 
slower-progressing individuals. This casts doubt on any results from this portion of the 
study. A repeat sampling of mice would be necessary to confirm the present study’s 
results. It may also be preferable to follow live mice with imaging technology such as 
ultrasound, in parallel with histological analyses, as this would give a more complete 
picture of when and how disease arises in KPC and KPC-G mice, and whether the 
two strains differ. 
 20 
Following KPC and KPC-G mice for survival showed the interesting result that 
a subset of KPC-G females survived much longer than any other mice in this study. 
While KPC and KPC-G males had nearly identical survival curves, the longest-lived 
KPC-G female lasted 100 days longer than her KPC counterpart. Forty percent of 
KPC-G females outlived all other mice on the study, including the entire KPC female 
cohort. Future study could include periodic live imaging of mice during such a survival 
experiment to determine how disease was developing over time, in addition to 




CHAPTER 3: Investigating the Relationship of Galectin-3 Binding Properties to 
its Suppression of Antitumor CD8+ T Cells 
 
Background and Rationale  
Studies have repeatedly shown the ability of galectin-3 to suppress immune 
cell function and contribute to a tumor-permissive microenvironment. It can do so 
through various pathways, both intracellularly and extracellularly, as discussed in 
Chapter 1. Our lab previously aimed to learn whether abrogation of galectin-3 in the 
tumor microenvironment would allow improved antitumor T cell function. To do this, 
our lab used HER-2/Neu transgenic (Neu-N) mice, which are engineered to express 
pre-oncogenic rodent Neu (Erbb2) via the mouse mammary tumor virus (MMTV) 
promoter, leading to expression of pre-oncogenic Neu in the mammary fat pad. As 
they reach an advanced age, these mice grow spontaneous breast tumors due to 
immune self-tolerance of the Neu antigen (46).  
To investigate antitumor immune responses in this model, my colleagues 
implanted a Neu-expressing tumor cell line in the mammary fat pad of 6-12 week old 
female NeuN mice and allowed it to grow until palpable. Mice then underwent a three-
day treatment course including a single dose of cyclophosphamide to deplete T-
regulatory cells, irradiated whole-cell Neu-directed tumor vaccine to activate DCs and 
induce presentation of the Neu antigen (47), and adoptive transfer of CD8+ T cells 
from a TCR-transgenic donor mouse expressing high-avidity anti-Neu CD8+ T cells 
(48). For TIL studies, mice were sacrificed two weeks after tumor implantation and 
tumor, spleen, and lymph nodes harvested and processed for analysis by flow 
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cytometry (Figure 3A). For studies of tumor-free survival, mice were given a lower 
initial tumor dose and an accelerated treatment course, and were then monitored for 
palpable tumor growth (Figure 3B).  
Our lab crossed the NeuN mice and the transgenic CD8+ T cell donor strain to 
background-matched Lgals3-/- (galectin-3 KO) animals, then compared CD8+ T cell 
effector response as indicated by duration of tumor-free survival and cytokine 
production by TILs. Interestingly, galectin-3 abrogation was correlated with larger 
percentages of TILs retaining their antitumor effector potential, as indicated by 
expression of interferon-gamma (IFNγ) and Granzyme B, but only when galectin-3 
was abrogated in both the tumor-bearing Neu-N mouse and the transgenic T cell 
donor mouse (20). This indicated that galectin-3 is capable of antitumor CD8+ T cell 
suppression, and that both the tumor-supportive microenvironment and the transgenic 
CD8+ T cells themselves could serve as sources of suppressive galectin-3. These 
findings were borne out in tumor-free survival experiments, where ninety percent of 
galectin-3 KO NeuN mice receiving galectin-3 KO CD8+ T cells with treatment were 
tumor-free sixty days after tumor implantation, but only fifty percent of normal Neu-N 
mice receiving normal transgenic T cells remained tumor-free at the same time point. 
These data taken together showed that galectin-3 is capable of antitumor CD8+ T cell 
suppression, and that this suppression leads to impaired ability to prevent tumor 
escape of immune control.  
The question then turned to how galectin-3 accomplished this suppression. Our 
lab has shown that high levels of galectin-3 can be detected on the surface of 
adoptively-transferred high-avidity CD8+ T cells that have trafficked into the tumor  
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Figure 3: Timeline of NeuN tumor-infiltrating lymphocyte and tumor-free 
survival experiments. To study the dynamics of antigen-specific T cell responses in 
the NeuN mouse model and their effect on tumor-free, survival, we use two different 
experimental timelines. A. For tumor-free survival, mice were given the minimal 
tumorigenic dose of NT2.5 Neu-expressing tumor cells followed on days 2, 3, and 4 
post-injection with single-dose cyclophosphamide, 3T3neuGM Neu-directed tumor 
vaccine, and adoptive transfer of high-avidity Neu-specific CD8+ T cells respectively. 
B. For tumor-infiltrating lymphocyte (TIL) analysis, mice were given a larger tumor 
dose and palpable tumors were verified. On days 7, 8, and 9 post-injection, the same 
three-day treatment course was given with a higher dose of high-avidity Neu-specific 




(tumor-infiltrating lymphocytes; TILs), but only low levels of surface galectin-3 are 
seen in the same cell population when it remains in the spleen or the tumor-draining 
lymph node (20, Figure). In separate experiments using healthy donor human CD8+ T 
cells and recombinant human galectin-3, our lab has shown that the addition of 
exogenous galectin-3 to the culture medium during in vitro T cell stimulation impairs 
their production of IFNγ (20). Taken together, these data imply that galectin-3 may be 
exercising its suppressive function on CD8+ T cells through a direct surface 
interaction, rather than through an intracellular mechanism or by mediating an effect 
through another cell type. Indeed, our lab has shown by Co-IP studies that galectin-3 
can interact with the checkpoint molecule LAG-3 on the CD8+ T cell surface. My 
colleague had proposed the model that secreted galectin-3 could bind LAG-3 at the 
CD8+ T cell surface, undergo oligomerization and lattice formation, and cause LAG-3 
clustering, transducing inhibitory signals into the CD8+ T cell through an aberrant 
mechanism (20). Our lab’s previous attempts to prove this mechanism downstream of 
LAG-3 have failed on a technical level, but the model remains a compelling 
hypothesis. 
Galectin-3 canonically binds beta-galactoside carbohydrate residues, 
particularly N-acetyllactosamine, which occur ubiquitously in the N- and O-linked 
branched oligosaccharides found on cell surface glycans (13,14). Additionally, it is 
known that the pressures of the tumor microenvironment can reprogram the cells 
present within it, including infiltrating immune cells (49,50). These reprogramming 
events have huge impacts on cellular metabolism, and can lead to changes in 
expression and activity of enzymes that control cell surface glycosylation (51,52). 
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Some of the glycosylation changes that occur within the tumor microenvironment 
could significantly impact the ability of galectin-3 to bind cell surface glycans. While 
the connection between galectin-3 and LAG-3 is compelling, the ubiquity of galectin-
3’s canonical ligand and the potential for altered glycosylation on tumor-infiltrating 
immune cells makes it unlikely that this would be its only avenue of CD8+ T cell 
suppression. I therefore first aimed to perform a survey of possible galectin-3 binding 
partners on the surface of CD8+ TILs, and whether these binding events were 
facilitated more by protein expression or by altered glycosylation in a tumor context. 
When my plans to interrogate the binding partners of galectin-3 on the surface 
of tumor-infiltrating CD8+ T cells proved unattainable, I decided to pursue an avenue 
of inquiry more within my range of expertise. I turned to the molecular properties of 
galectin-3 itself, and how these could impact its ability to suppress T cell effector 
function. Galectin-3 binds its beta-galactoside ligand through its CRD. It also 
oligomerizes with other galectin-3 molecules through its NTD, as discussed in Chapter 
1. While it is clear that galectin-3 has a suppressive effect upon tumor-infiltrating CD8+ 
T cells, and seems likely that this suppression may occur through a binding event at 
the T cell surface, it is unclear how the dual binding domains of galectin-3 influence 
its ability to suppress. I therefore decided to investigate the biochemical properties of 
galectin-3, aiming to develop an in vitro system to model its suppression of tumor-
infiltrating CD8+ T cells, and using this system to learn how its binding properties 




To survey the glycan binding partners of galectin-3 on the TIL surface, I 
prepared whole cell protein lysates from freshly-isolated C57Bl/6 wildtype mouse T 
cells to use in the optimization of my assay, a lectin blot modeled after a standard 
Western blot. In this procedure, protein samples are prepared from lysates and run on 
a protein gel, then transferred to a membrane as with a Western blot. After blocking 
of the membrane, it is first incubated with recombinant mouse galectin-3, followed by 
anti-galectin-3 primary antibody and an HRP-conjugated secondary antibody. My 
intent was to prepare membrane protein extracts from adoptively-transferred 
transgenic CD8+ T cells from either the spleen, lymph node, or tumor of our NeuN 
mouse model of tumor tolerance, and to compare the lectin blot band pattern seen in 
each sample to determine whether trafficking into the tumor microenvironment altered 
the cohort of galectin-3 binding partners in the assay.  
My next goal was to design an assay to identify these protein binding partners. 
Using the lectin blot for this purpose would have been technically challenging as it 
would have required precisely cutting bands from a protein gel and preparing those 
samples for mass spectrometry to determine the identity of the proteins involved. I 
therefore worked to design a pull-down assay, similar to an immunoprecipitation, 
where a labeled recombinant galectin-3 would be added to membrane extracts from 
the cell populations described above. A bead-conjugated antibody to the label would 
be added, and binding partners could be eluted from galectin-3 using excess lactose. 
The goal of this approach was first to identify the binding partners of galectin-3 on TILs 
as opposed to T cells remaining in the spleen or lymph nodes, and then to focus on 
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these proteins, determining whether their expression is upregulated upon entry into 
the tumor microenvironment, or whether they undergo changes in glycosylation due 
to the metabolic effects of tumor infiltration. Through these studies, I hoped to learn 
what candidate proteins might mediate galectin-3 suppression of CD8+ TILs, whether 
these proteins become binding targets by differential expression or differential 
glycosylation, and then to use these answers to elucidate the mechanism of 
suppression. It also would allow us to propose novel avenues for targeting galectin-3 
in the tumor microenvironment, and could eventually lead to therapies that cause 
tumors to be more susceptible to immunotherapy.  
 To investigate how the dual binding domains of galectin-3 impact its ability to 
suppress CD8+ T cells in a tumor context, I used an expression vector previously made 
in our lab containing mouse galectin-3 fused to a secretion sequence, under 
transcriptional control of the CMV promoter (pcDNA3.3-mGal3S). I used site-directed 
mutagenesis to create three mutant versions of this plasmid: a point mutant of the 
carbohydrate recognition domain (CRD) which should not be able to bind beta-
galactoside carbohydrate residues, a truncation mutant missing the N-terminal 
domain (NTD) which should not be able to oligomerize, and a double mutant. For the 
CRD point mutant, I chose Arginine 176, a key player in the binding of beta 
galactosides in the CRD cleft. Initially I mutated this residue to Glycine (R176G). For 
the NTD truncation mutant, I engineered a version of the vector that deleted every N-
terminal residue of galectin-3 up to the CRD, excepting the secretion sequence. 
I had previously utilized the bacterium Escherichia coli (E. coli) for the 
production of recombinant galectin-3, but later found that it was impossible to fully 
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remove lipopolysaccharide (LPS), otherwise referred to as endotoxin, from the purified 
protein. I confirmed this issue in the literature (53), and learned that since galectin-3 
naturally binds to LPS, full removal of endotoxin is not possible from such samples. 
This is also an issue with commercially-available recombinant galectin-3, which is 
generally produced in E. coli. I therefore chose to optimize a mammalian system for 
recombinant protein production by transiently transfecting HEK-293T cells with normal 
galectin-3 or mutant forms. The secretion sequence engineered onto the galectin-3 N-
terminus forces secretion of the majority of recombinant protein, causing it to undergo 
all physiologically relevant posttranslational modifications, and allowing it to be purified 
from the cell culture supernatant for use in in vitro assays. Verification of galectin-3 
secretion into the cell culture supernatant was performed by Western blot, comparing 
supernatant samples to 293T whole-cell protein lysates. 
To purify recombinant galectin-3 from cell supernatants requires a multi-step 
process. The process begins with ammonium sulfate precipitation of galectin-3 directly 
from the culture supernatant. The protein pellets produced by precipitation are re-
solubilized in protein buffer and subjected to size exclusion chromatography. The 
relevant fractions then go through ion exchange chromatography, beginning with 
anion exchange and followed by cation exchange. At each step, the fractions 
containing galectin-3 are verified by Western blot and passed to the next purification 
step. Once ion exchange is complete, galectin-3 purity is established by overloading 
protein in one well of a gel and staining the gel for total protein to determine whether 
any other contaminants remain in the sample. If so, ion exchange steps can be 
repeated as necessary. 
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While optimizing protein purification protocols, I looked for an assay to test 
activity of recombinant galectin-3 in an in vitro system. My goal was to model the 
activity of adoptively transferred high-avidity donor T cells in our NeuN system. In the 
mouse model, these naïve cells are adoptively transferred by intravenous injection, 
where they can then traffic to the lymph node and become primed by dendritic cell 
populations induced by the Neu-directed tumor vaccine. Over the next few days, these 
T cells travel to the tumor site, where they are re-stimulated by their cognate antigen 
on tumor cells, produce effector cytokines, and attempt tumor cell killing. I felt that the 
best way to model this initial priming and reactivation was to perform the initial priming 
in vivo, isolate the activated cells from the mouse, and perform an in vitro re-
stimulation to assess the effector potential these T cells would have if they were 
trafficking to a tumor site. Our lab developed such a protocol for past assessments of 
previously in vivo activated T cells, and I used this with some modification.  
This protocol uses the same transgenic CD8+ T cells we examine in the NeuN 
model, adoptively transferred into wildtype FVB/N mice. The mice received the Neu-
directed tumor vaccine utilized in the NeuN model, concurrently with the adoptively-
transferred naïve T cells, and activation was allowed to proceed in vivo for 7 days. At 
this time point, I harvested spleen and lymph nodes from these mice and proceeded 
with a pan-T cell isolation. Isolated T cells, which included both the adoptively 
transferred transgenic CD8+ T cells and endogenous FVB/N T cells, were then plated 
with T2-Dq cells, a TAP-deficient human cell line engineered for surface expression of 
empty mouse H2-Dq MHC class I. For this experiment, these cells were pulsed with 
the Neu antigenic peptide for antigen-specific re-stimulation of adoptively-transferred 
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transgenic T cells. The re-stimulation was performed by co-culturing isolated T cells 
with pulsed and washed T2-Dq cells for six hours in T cell medium containing 
monensin, and was followed by surface staining and intracellular cytokine staining 
(ICS) for flow cytometry, to assess the effector potential of the adoptively-transferred 
CD8+ T cells after in vivo activation. This re-stimulation step is meant to model the re-
activation of CD8+ T cells that infiltrate tumor, but to provide an environment where 
we may assess the suppressive capability of exogenous galectin-3 in the absence of 
other suppressive factors. 
I plan to add purified galectin-3 to the in vitro re-stimulation culture to see 
whether its suppressive effects manifest in lower levels of effector cytokine production. 
If we do see such suppression, and thereby confirm a direct suppression of T cells by 
galectin-3, I hope to test the suppressive capability of mutant forms of galectin-3. This 
may elucidate the question of whether carbohydrate binding, oligomerization, or both 
binding properties of galectin-3 are most essential to its suppressive effects on tumor-
infiltrating CD8+ T cells. 
  
 31 
Materials and Methods 
 
Site-Directed Mutagenesis 
 To achieve site-directed mutagenesis of the galectin-3 expression vector 
(pcDNA3.3-mGal3S), I used the Q5 Site-Directed Mutagenesis Kit (E0554, New 
England Biolabs). This kit requires the design of 5’ to 5’ back-to-back PCR primers, 
with specific primer design dependent on the intended mutation. For point mutations, 
one of the two primers carries the complementary base for the intended point mutation 
and should be designed to cover that portion of sequence. For deletion mutations, 
rather than abutting each other when annealed to template, the primers’ 5’ ends 
should directly flank the intended deletion site. For short insertion mutations, one 
primer will have the desired insertion sequence at its 5’ end, such that the 5’ end of 
one primer abuts the middle of the insertion primer when annealed to the template 
DNA. For longer insertions, each primer should carry half of the intended insertion on 
the 5’ end with their middles abutting when annealed to the template DNA. I used the 
NEBaseChanger online tool for initial primer design, then checked the proposed 
primer sequences for redundant binding sites in the expression vector using 
SnapGene software. Once primer sequences were optimized, oligonucleotides were 
ordered from Integrated DNA Technologies, resuspended at 100uM, and diluted to 
10uM for use in PCR.  
The Q5 kit uses PCR with a high-fidelity polymerase to produce linear mutated 
vector sequences. PCR reactions were prepared as indicated in the kit manual, with 
5-10 ng input DNA used per reaction. The PCR was run in a thermal cycler on the 
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program indicated in the kit manual, using the annealing temperature suggested by 
NEBaseChanger for each primer set and setting the extension time at 2 minutes per 
cycle to accommodate vector size. If primer sets were optimized beyond what was 
suggested by NEBaseChanger, optimal annealing temperature was determined using 
a standard gradient PCR protocol. PCR was then followed with the KLD reaction as 
detailed in the kit manual, which uses a kinase and ligase to circularize the vector, 
and contains Dpn I, a restriction enzyme which cleaves DNA at the site of methylated 
adenine in the sequence GmA|TC, thereby removing all template DNA grown in a 
bacterial system and leaving the PCR product vectors intact. DNA prepared from 
bacteria transformed with plasmid PCR product was used to confirm mutagenesis by 
Sanger sequencing performed by Hopkins Genetic Resources Core Facility (GRCF). 
 
Bacterial Transformation, Plating, Culture Growth, and Storage 
 I performed all transformations using chemically-competent TOP10 E. coli 
(C4040, Invitrogen) with either the standard or quick transformation protocols. I plated 
transformants on Luria Broth (LB) agar plates containing Ampicillin (Amp) for antibiotic 
selection of transformed colonies. I picked five colonies from each plate to seed 5 mL 
LB-Amp bacterial cultures for glycerol stocks and minipreps of plasmid DNA. I 
prepared glycerol stocks by mixing 500 µL bacterial culture with 500 µL 20% glycerol, 
then stored these at -80ºC. I used the remainder of each culture in the QIAprep Spin 
Miniprep Kit (27104, QIAGEN) to extract plasmid DNA, which was diluted to prepare 
for sequencing. After sequence verification, I used glycerol stocks of verified clones 
to seed 5 mL LB-Amp cultures, which were then used to seed 150 mL LB-Amp 
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cultures. I spun down the large cultures in 200 mL plastic centrifuge bottles to obtain 
pellets, which were then used in the ZymoPURE II Plasmid Maxiprep Kit (D4202, 
Zymo Research) to prepare maxipreps of low-endotoxin plasmid DNA. All plated 
cultures were incubated overnight in a 37ºC cabinet incubator. All liquid cultures were 
incubated overnight in a 37ºC shaking incubator at 200 rpm. 
 
Transfection of HEK-293T Cells  
 Low passage number HEK-239T cells were thawed from lab freezer stocks and 
brought up in T175 flasks containing Complete DMEM (Dulbecco’s Modified Eagle’s 
Medium supplemented with 10% FBS Benchmark, 1% L-Glutamine, and 0.5% 
Penicillin-Streptomycin). When cells reached 90% confluence, the culture medium 
was removed and the cell bed was washed with cold 1X phosphate-buffered saline 
(PBS). PBS was removed by aspiration and 5 mL 0.25% Trypsin was added. Cells 
were trypsinized for 1 minute at 37ºC. After trypsinization, I harvested the cells using 
20 mL Complete DMEM and centrifuged for 5 minutes at 4ºC, 1500 rpm. Cells were 
resuspended and counted, then resuspended in antibiotic-free DMEM (as above 
without Penicillin-Streptomycin) at a concentration of 5x105 cells per 1 mL of medium. 
The desired amount of cell suspension was then plated in an appropriately sized 
container for transfections the following day.  
 On the day of transfection, confluence of 70-90% was confirmed, then cell 
culture medium was changed from antibiotic-free DMEM to Low-Serum DMEM 
(Dulbecco’s Modified Eagle’s Medium supplemented with 2.5% FBS and 1% L-
Glutamine). Cells remained in the incubator during transfection preparation. All 
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transfections were prepared using a standard Lipofectamine 3000 protocol, where for 
every 1x106  transfected cells,125µL Opti-MEM was mixed with 3.75 µL Lipofectamine 
3000 and 125 µL Opti-MEM was mixed with 5µg of transfection vector DNA and 10µL 
P3000 reagent. The two transfection mixes were combined and incubated for 10 
minutes at room temperature before being added to the culture medium of the 
transfected cells and mixed gently to incorporate. Transfections were left for 48-96 
hours before beginning protein purification from cell supernatants. 
 
Preparation of Protein Samples for Lectin Blot 
 To prepare lysates for lectin blot optimization, CD8+ T cells were isolated from 
cell suspensions prepared from C57Bl/6 mouse pooled spleen and lymph nodes. IP 
Lysis Buffer was prepared by supplementation of Pierce Co-IP Lysis Buffer (87788, 
Thermo Fisher) with phenylmethylsulfonyl fluoride (PMSF), dithiothreitol (DTT), and a 
protease inhibitor cocktail (118361530001, Roche). 400 µL of supplemented lysis 
buffer was added to a cell pellet of 1.75x107 CD8+ T cells and pipetted up and down 
to resuspend. This suspension was incubated on ice for 30 minutes. Cells were them 
subjected to two rounds of sonication for 8 seconds each with a 30 second rest on ice 
in between. Lysates were centrifuged for 15 minutes at 14,000 x g in a 4ºC benchtop 
microcentrifuge. The supernatant was collected as the final protein lysate.  
 Lysate was diluted 1:5 in diH2O, then 35µL diluted lysate was added to 12.5 µL 
4X Sample Buffer and 2.5 µL 20X Reducing Agent and pipetted up and down to mix. 
Samples were boiled for 10 minutes at 100ºC, then cooled to room temperature and 
centrifuged before gel run. 
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Preparation of Protein Samples for Western Blot 
 To test for expression and secretion of transfected protein, transfected cell 
supernatants and pellets were harvested in parallel. Protein input was normalized by 
dividing total supernatant volume by total number of cells counted. A known number 
of cells was pelleted to make protein lysates, and a corresponding proportion of 
supernatant was used as input for protein samples.  
 To make protein samples from lysates, cells were pelleted, then lysed directly 
by resuspension in 1X Laemmli Sample Buffer. To make protein samples from 
supernatant, the appropriate supernatant volume was mixed with 5X Laemmli Sample 
Buffer (60 mM Tris-HCl pH 6.8, 2% sodium dodecyl sulfate, 10% glycerol, 5% beta 
mercaptoethanol, 0.01% bromophenol blue) and water as necessary to achieve a 1X 
buffer concentration. After sample preparation, all protein samples were boiled for 5 
minutes at 100ºC. 
 
Protein Gel Runs 
 Boiled samples were cooled to room temperature and centrifuged, then loaded 
into 15-well 12% Bis-Tris precast gels (NP0343, Invitrogen) with Precision Plus Dual 
Color Protein Standard (1610374, BioRad) used as a ladder. Gels were run at 200V 
in tanks containing 1X NuPage MOPS buffer (NP0001, Invitrogen) for an appropriate 





Total Protein Staining 
 To detect total protein in gel run samples, gels were removed from plastic cases 
and rinsed in large volume (about 100 mL) diH2O 3 times for 5 minutes each on an 
orbital shaker. Water rinses were discarded, then gels were submerged in 20 mL 
SimplyBlue Safestain (LC6060, Invitrogen) and incubated on an orbital shaker at room 
temperature for 1 hour.  
 Stain was discarded, then gels were rinsed from 3 hours to overnight in excess 
volume of diH2O. This water wash was repeated 1-2 times to achieve a clear 
background and sharp protein gel bands. De-stained gels were imaged using a 
conventional flatbed scanner.  
 
Lectin Blot for Galectin-3 Binding Partners 
 Gels were set up in Bio Rad Criterion transfer apparatus to transfer to 
nitrocellulose membrane. Transfer buffer was made fresh by combining 1.6L diH2O, 
400 mL methanol, 28.8 g UltraPure Glycine, and 6.06g Tris, and allowing to mix well 
on a stir plate. Transfer buffer was added to tank, and transfer run at 5V in an ice 
bucket in the 4ºC cold room overnight.  
 Transferred membranes were rinsed in fresh 1X Tris-Borate-Saline, 0.1% 
Tween (TBS-T) buffer for 5 minutes, then underwent blocking of nonspecific binding 
by incubating for one hour at room temperature in 3% bovine serum albumin (BSA) in 
1X TBS-T. After blocking, buffer was discarded and recombinant mouse galectin-3 
(599804, BioLegend) was added to the blot at a concentration of 0.5 µg/mL in blocking 
buffer and blots were incubated overnight at 4ºC.  
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 After blocking, galectin-3 suspension was discarded and blot was washed in 
fresh 1X TBS-T, four times for 5 minutes each time on an orbital shaker. After washes, 
purified anti-galectin-3 primary antibody (125401, Biolegend) was added at a 1:1000 
dilution in blocking buffer. Blot was incubated in primary antibody for one hour at room 
temperature on a rocker. After incubation, the four TBS-T washes were repeated. 
 Secondary antibody dilution was performed by adding goat anti-rat HRP 
secondary antibody (NA935, GE Healthcare) to blocking buffer at a concentration of 
1:5000. Secondary antibody was added to blot and incubated for one hour at room 
temperature on a rocker, after which the four TBS-T washes were repeated.  
 After the final wash, blots were treated with a 1:1 mix of Pico Plus 
Chemiluminescent Substrate (34579, Thermo Fisher) for development. Blot was 
incubated for 5 minutes at room temperature, then substrate was removed for blot 
ECL imaging in a UVP digital imager. 
 
Western Blot for Galectin-3 Expression 
 To perform galectin-3 Western blot, precast gels were removed from plastic 
cases and rinsed in diH2O, then cut to size and transferred onto nitrocellulose 
membrane using the Invitrogen iBlot 2 dry transfer device. After transfer, membranes 
were trimmed and placed in a solution of 3% BSA in 1X TBS-T for blocking of 
nonspecific binding interactions. Blocking was performed either for one hour at room 
temperature or overnight at 4ºC.  
 After blocking, excess blocking buffer was discarded and a solution of purified 
anti-galectin-3 primary antibody (126701, BioLegend) diluted 1:1000 in blocking buffer 
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was added. Incubation was performed either for 2 hours at room temperature or 
overnight at 4ºC. After incubation, primary antibody solution was collected and stored 
at 4ºC for reuse. Blots were washed in 1X TBS-T four times for 3 minutes each on an 
orbital shaker.  
 A preparation of secondary antibody (NXA931, GE Healthcare) was made in 
blocking buffer at 1:20,000 concentration and added to each blot after the final wash 
was discarded. Incubation was performed for 1 hour at room temperature, after which 
secondary antibody was discarded. Blots were washed in 1X TBS-T four times for 3 
minutes each on an orbital shaker. 
 Blots were placed in clean plastic dishes and a fresh 1:1 preparation of Pico 
Plus Chemiluminescent Substrate (34579, Thermo Fisher) was added for detection. 
Blots were incubated for 5 minutes at room temperature, then excess substrate was 
removed and blots were placed in plastic sheet protectors for digital imaging of ECL 
signal. 
 In the UVP digital imager, minimal exposure time was used to allow all bands 
present to become visible. Blot images were inverted for easier visibility of bands and 
any adjustments of gamma signal were performed on contiguous blots only so that 
band brightness was true to actual relative intensity of samples on the same blot. 
When images from multiple blots have been compared, exposure times have been 





Ammonium Sulfate Precipitation 
 To perform an initial purification of galectin-3, precipitation from the transfected 
cell supernatant with saturated ammonium sulfate solution was performed. Saturated 
ammonium sulfate was prepared using a standard table of mass of ammonium sulfate 
powder to volume of diH2O (54). To determine the optimal concentration for 
precipitation of galectin-3 while leaving behind as many contaminants as possible, 
ammonium sulfate cuts were performed. We performed three sets of serial cuts, which 
involves raising the percentage of ammonium sulfate in the supernatant from zero to 
either 20, 30, or 40 percent. Samples were then centrifuged for 8 minutes at 17,000 x 
g in a benchtop refrigerated microcentrifuge at 4ºC to obtain a total centrifugation of 
100,000 g-minutes. 
 After centrifugation, remaining supernatant was removed from the protein pellet 
(if any was visible) and concentration of ammonium sulfate was raised from 20, 30, or 
40 percent to either 40, 50, or 60 percent. Samples were centrifuged a second time 
and supernatants were removed from pellets. For the final round, percentages of 
ammonium sulfate were raised from 40, 50, or 60 percent to 80 percent in all samples, 
a concentration at which nearly all protein should precipitate. Supernatant was 
discarded. 
 After cuts were performed, protein pellets were resuspended in a protein buffer 
containing 10 mM HEPES and 100mM sodium chloride at volumes that would 
normalize their protein concentration based on the volume of original cell supernatant 
that was used to produce each pellet. Once normalized, protein samples for gel runs 
were prepared as described above and gels were run for total protein assessment and 
 40 
galectin-3 detection by Western blot. Galectin-3 was detected entirely in the pellet of 
the 30-50% ammonium sulfate cut, so for ongoing purifications, supernatant 
ammonium sulfate concentration was raised to 30%, allowed to equilibrate, then 
raised to 50% before pellet centrifugation.  
 Protein pellets were allowed to dry as much as possible, then were stored on 
wet ice at 4ºC until resuspension for chromatography column runs. 
 
Size Exclusion Chromatography 
 Protein pellets were resuspended in a buffer containing 10 mM HEPES, 100 
mM sodium chloride, and 20 mM lactose in milliQ diH2O. All pellets must be 
resuspended at a volume not exceeding 14 mLs. After resuspension, proteins were 
filtered using 0.2 µm syringe filters before loading into a loop and attaching to the 
BioRad NGC Quest 10 chromatography system (7880001, BioRad). The protein 
sample was loaded onto a Hi-Prep 26/60 Sephacryl S300 size-exclusion column 
(17119601, GE Healthcare) previously equilibrated with the sample buffer described 
above, run at 1 mL per minute. Fractions were collected and total protein was 
assessed by SimplyBlue staining of protein gels as described above. Galectin-3 was 
located by Western blot. 
 
Ion Exchange Chromatography 
 Pooled protein fractions from the size exclusion column run were diluted 1:5 in 
milliQ diH2O to dilute sodium chloride to 20mM before loading into a loop and attaching 
to the chromatography system. An ENrichQ anion exchange column (780-0001, 
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BioRad) was equilibrated with a protein buffer containing 10mM HEPES, 20 mM 
sodium chloride, and 20 mM lactose. The sample was run over the column at 0.5 
mL/min, with 8mL fractions collected during flow through and 1 mL fractions collected 
during segmented gradient elution. Fractions were collected and total protein was 
assessed by SimplyBlue staining of protein gels as described above. Galectin-3 was 
located by Western blot.  
 
Mice 
 NeuN (FVB/N-Tg(MMTVneu)202Mul/J) mice were originally purchased from 
Jackson Laboratories and bred in-house. NeuN Lgals3-/- mice were bred as 
previously described (20). FVB/N background mice were purchased as needed from 
Jackson Laboratories. High-avidity neu-specific TCR transgenic mice (Clone100) 
were produced as previously described and avidity verified by tetramer staining (48). 
Clone100 Lagls3-/- mice were produced as previously described (20). Animals were 
housed in the Johns Hopkins Animal Facility and cared for according to protocols 
approved by the Johns Hopkins Animal Care and Use Committee. 
 
Adoptive Transfer and Vaccine Preparation and Administration 
 For ex-vivo experiments, spleens and inguinal, axillary, brachial, and cervical 
lymph nodes were harvested from Clone100 mice. Organs were dissociated into 
single cell suspension and red blood cells were lysed, then CD8+ T cell isolation was 
performed using a Mouse CD8+ T Cell Isolation Kit (19853, STEMCELL). CD8+ T cells 
were counted, then stained with CellTrace carboxyfluorescein succinimidyl ester 
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(CFSE) or CellTrace Violet proliferation dye, incubated, and washed per 
manufacturer’s protocol. When using CellTrace Violet, one tenth of the recommended 
proliferation dye was used. Cells were then washed three times in 30 mL ice cold 1X 
PBS. On last wash, cells were counted, and the final pellet was resuspended at 
1.2x106 cells/mL in 1X PBS. 
 3T3neuGM vaccine cells or 3T3GM mock vaccine cells were cultured in CRIP 
VAC medium (DMEM, 10% FBS, 1% L-Glutamine, 1% non-essential amino acids, 1% 
sodium pyruvate, 0.5% penicillin-streptomycin, supplemented with methotrexate for 
selection) or CRIP MOCK medium (as above without methotrexate) until confluent. 
Cells were trypsinized and harvested, then counted and washed three times in ice 
cold 1X PBS. On the last wash cells were counted again, then resuspended at 1x107 
cells per mL in 1X PBS. Cells were irradiated at 50 Gy in a CIXD Biological X-Ray 
Irradiator (Xstrahl).  
 Isolated Clone100 CD8+ T cells were injected intravenously into FVB/N 
recipients (6x106 cells per mouse in a 500 µL injection). Irradiated 3T3neuGM cells or 
3T3GM mock cells were given by subcutaneous injection of 100 µL and 1x106 cells 
into three of four limbs of each FVB/N adoptive transfer recipient. 
 
T Cell Harvest and Re-stimulation In Vitro 
 To prepare the re-stimulation experiment, T2-Dq cells were cultured in EBV 
medium (RPMI, 10% FBS, 1% L-Glutamine, 1% non-essential amino acids, 1% 
sodium pyruvate, 0.5% penicillin-streptomycin, with hygromycin added for selection). 
Upon confluence, these cells were harvested and resuspended at 1x106 cells per mL 
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in serum-free Complete RPMI (RPMI, 1% L-Glutamine, 0.5% penicillin-streptomycin). 
Neu oncogenic peptide (RNEU420-429, PDSLRDLSVF) or control peptide (NP118-126, 
RPQASGVYM) were added to the cell suspension to achieve peptide concentrations 
of 2.5 µg per mL of cells. Peptide pulse was performed at room temperature for at 
least two hours with gentle slow shaking on an orbital shaker. After pulse, T2-Dq cells 
were washed in Complete RPMI (RPMI 1640, 10% FBS, 1% L-Glutamine, 0.5% 
penicillin-streptomycin) and resuspended at 1x106 cells per mL in Complete RPMI for 
plating in the re-stimulation. 
 After seven days of in vivo stimulaton by vaccine administration, adoptively 
transferred high-avidity neu-antigen-specific T cells were harvested from recipient 
FVB/N mice by dissecting spleens and inguinal, axillary, brachial, and cervical lymph 
nodes. Single-cell suspensions were prepared from organ dissociation and red blood 
cells were lysed. A Mouse Pan-T Cell Isolation Kit (19851, STEMCELL) was used to 
isolate all T cells from this suspension. Cells were counted and resuspended at 4x106 
cells per mL in Complete RPMI for plating in the re-stimulation. 
 To plate the cells for re-stimulation, 500µL of T cell suspension (2x106 cells) 
and 500µL of peptide-pulsed T2-Dq cells (5x105 cells) were combined in each well of 
a 48-well culture plate. 0.67 µL monensin (BD GolgiStop) was added to each well and 
each well was pipetted up and down gently to mix. Cells were allowed to undergo re-





Flow Cytometry and Intracellular Cytokine Staining 
 After re-stimulation, cells from each well were harvested and spun down, then 
re-suspended in 100 µL PBS and plated in a 96-well V-bottom assay plate to prepare 
for flow cytometry staining. For viability staining, a 1:1000 dilution of Live/Dead Aqua 
Stain stock (L34957, Thermo Fisher) in 1X PBS was made, and all viability-stained 
wells were resuspended in 100 µL of this stain. Staining was performed for 30 minutes 
at 4ºC. Cells were washed twice in 1X PBS. 
 A 5 µg per mL dilution of Mouse BD Fc Block (553141, BD) was made in 1X 
FACS buffer (PBS, 2% FBS, 2 mM EDTA) and added to cells to block non-specific 
binding of fluorescent antibodies. Cells were incubated for 15 minutes at 4ºC, then 
washed once in FACS buffer. 
 Fluorescent antibody dilutions were prepared as needed and antibodies were 
added as single stains or cocktails to each well of cells. Surface staining was allowed 
to proceed for either 20 minutes at room temperature or overnight at 4ºC. Cells were 
washed twice in 1X FACS buffer before proceeding to intracellular stain. 
 To fix and permeabilize cells, all pelleted cells in the plate were resuspended 
vigorously in 100 µL per well of BD Fixation/Permeabilization solution (554722, BD) 
and incubated for 20 minutes at 4ºC protected from light. A 1X solution of BD 
PermWash (554723, BD) was prepared by diluting the provided reagent 1:10 in diH2O. 
Cells were washed twice in 1X BD PermWash, then resuspended in 100µL per well 
of 1X BD PermWash for the addition of cytokine antibodies for intracellular stain.  
Intracellular stains were allowed to proceed for 30 minutes at 4ºC, then cells were 
washed twice in 1X BD PermWash, once in 1X FACS buffer, and resuspended in 250 
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µL per well of 1X FACS buffer for running and analysis on a Beckman Coulter Cytoflex. 
Appropriate single stain compensation controls, isotype antibody staining controls, 
and fluorescence minus one controls were included in the experiment. Flow cytometry 
analysis was performed with Beckman Coulter CytExpert software, and graphs of 
mean fluorescence intensity data were made and analyzed using GraphPad Prism 
software. Comparisons of mean fluorescence intensity between RNEU and NP 






Proteins Bound by Galectin-3 Are Detectable by Lectin Blot, but Complicated to 
Identify 
 To identify galectin-3 binding partners on tumor-infiltrating CD8+ T cells, I 
wanted to develop a lectin blot assay. The lectin blot is similar to a traditional Western 
blot, but introduces a known quantity of a lectin of choice in place of a primary 
antibody. Rather than detecting a protein run on the original gel, the lectin is detected 
using a tag and antibody or a series of antibodies. I planned to make membrane 
protein extracts from adoptively-transferred tumor-infiltrating CD8+ T cells to compare 
to adoptively-transferred cells remaining in the spleen and lymph nodes of vaccinated 
tumor-bearing NeuN mice, but I performed assay optimization using lysates made 
from the CD8+ T cells of wildtype C57Bl/6 mice.  
 The challenge of optimizing the lectin blot was achieving a clean assay. Lectin 
blots traditionally utilize a tagged or biotinylated lectin so that detection may be 
performed with a single antibody incubation after washing excess lectin. Since this 
was unavailable, I used recombinant mouse galectin-3 detected with primary and 
secondary antibodies I had successfully used for Western blot.  
 I successfully optimized the lectin blot, showing that the blot results were not 
due to interactions of the primary or secondary antibodies with the protein sample. 
Unfortunately, the resulting blot showed numerous bands located in close proximity to 
one another (Figure 4). My plan for protein identification had been to run two protein 
gels in parallel, using one for lectin blot and retaining one from which to excise protein  
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Figure 4: Optimized lectin blot shows specific binding of galectin-3 to proteins 
present in protein lysates prepared from C57Bl/6 CD8+ T cells. CD8+ T cells were 
isolated from wildtype C57Bl/6 mice and lysates prepared from isolated cells for 
protein gel runs. Gels were transferred to nitrocellulose membrane and blotted with 
recombinant mouse galectin-3, primary anti-galectin-3 antibody, and secondary anti-
rat HRP antibody. Blot was developed using ECL development reagents. Discrete 
bands were visualized, but could not be isolated for further downstream analysis. 
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bands for identification by mass spectrometry. This was not feasible with the resulting 
band pattern. I needed to develop an assay that would allow a similar sampling of a 
protein extract without the complicating factor of excision from a gel for the 
identification of binding partner candidates. I therefore attempted the development of 
a pull-down assay similar to a conventional immunoprecipitation, but assay design 
failed at a technical level and I focused instead on studies of how the intrinsic 
properties of galectin-3 impact its suppressive functions. 
  
Secretion of Galectin-3 Mutant Forms from Transiently Transfected HEK-293T Cells 
is Impaired 
 To test the mammalian transient transfection system, I performed small-scale 
transfections with the expression vectors containing galectin-3, the CRD point mutant, 
the NTD truncation mutant, or the double mutant. All vectors were engineered with a 
secretion sequence on the end coding the N-terminus of the protein to force secretion 
into the cell supernatant (Figure 5A).  
 When analyzed by Western blot, it became clear that the mutant forms of 
galectin-3 were not being successfully secreted (Figure 5B). While more than half of 
the normal galectin-3 was found secreted into the supernatant, a much smaller fraction 
of the point mutant was detected there. The defect was even more notable in the 
truncation mutant and double mutant. This was an expected outcome for the mutants 
truncated at the N-terminus, as this could cause the engineered secretion sequence 
to become buried in the globular CRD, but was an unexpected outcome for 
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Figure 5: Engineered expression vectors for transfection and purification of 
mutant forms of recombinant mouse galectin-3 show secretion defects upon 
transfection. A. Schematic of engineered expression vectors for forced-secretion 
galectin-3, the CRD point mutant, NTD truncation mutant, and double mutant. B. 
Secretion defects are seen when galectin-3 and mutant forms are detected by 
Western blot in transfected cell lysates or supernatants. Gel lanes shown contain 
protein samples made from the following transfected cell lysates or supernatants: 1, 
pcDNA3.3-mGal3S, with input diluted 1:10; 2, pcDNA3.3-mGal3S-tNTD; 3, 
pcDNA3.3-mGal3S-CRDR176G; 4, pcDNA3.3-mGal3S-tNTD/CRDR176G. Normal 
monomeric galectin-3 can be visualized in bands at ~29-31 kDa. Truncated galectin-
3 mutants are visualized as bands at ~14-16 kD. All mutants have some defect in 






the point mutant, which I hypothesized would retain a similar structure and properties 
to those of normal galectin-3.  
 
Transfection of Galectin-3 into HEK-293T Cells May Be Performed in Low-Serum 
Conditions 
 When developing and testing protein purification strategies for galectin-3 from 
the supernatant of HEK-293T cells, a major concern was the presence of protein 
contaminants from the cell culture medium. While it is important to purify a secreted 
form of galectin-3 so that it retains its pertinent post-translational modifications, the 
serum present in cell culture medium is one of the largest sources of protein 
contamination to this system. I therefore wanted to test the capability of transfected 
HEK-293T cells to produce recombinant galectin-3 when transfected in culture 
medium containing low or no added serum.  
 I seeded cells overnight for transfection the following morning. Directly prior to 
transfection, the normal transfection culture medium was removed and replaced with 
either fresh transfection medium (10% fetal bovine serum), 5%, 2.5%, or 0% serum 
medium. I performed the transfections and incubated the cells for 48 hours. After 
incubation, I harvested the supernatants from each transfection and prepared protein 
samples for galectin-3 Western blot. The blot results showed that cells transfected 
with galectin-3 produced equal amounts of protein as long as the culture medium 
contained some level of fetal bovine serum (Figure 6). Unsurprisingly, transfecting 
cells in serum-free medium caused cellular dysfunction that led to very low levels of 
recombinant protein being produced, but the amount of galectin-3 produced in the 
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Figure 6: Transfection of galectin-3 into HEK-293T cells is successful in low-
serum conditions. To attempt to decrease the concentration of bovine serum 
albumin (BSA) in the supernatant of transfected cells, transfections (mock 
transfection, pcDNA3.3-EV, or pcDNA3.3-mGal3S) were performed in culture medium 
supplemented with either no fetal bovine serum (FBS), 2.5% FBS, 5% FBS, or 10% 
(normal) FBS. Protein samples for gel run were made from cell supernatants 72 hours 
following transfection, and were analyzed by Western blot for galectin-3. Gel lanes 
shown contain protein samples made from the following transfected cell supernatants: 
1, mock, no FBS; 2, mock, 2.5% FBS; 3, mock, 5% FBS; 4, mock, 10% FBS; 5, EV, 
no FBS; 6, EV, 2.5% FBS; 7, EV, 5% FBS; 8, EV, 10% FBS; 9, mGal3S, no FBS; 10, 
mGal3S, 2.5% FBS; 11, mGal3S, 5% FBS; 12, mGal3S, 10% FBS. As expected, no 
galectin-3 was detected by Western blot for mock or empty vector transfections. Only 
cells grown in medium containing no FBS showed any defect in production of galectin-
3. Monomeric galectin-3 is detected as a band of ~29-31kDa. 
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10%, 5%, and 2.5% serum conditions was very similar. Based on these data, I used 
2.5% serum culture medium for all large-scale transfections used in protein 
purification.  
 
Purification of Recombinant Galectin-3 Requires Excess Lactose and a Multi-Step 
Approach 
 While working to optimize the transfection and secretion of galectin-3 mutant 
forms, I began the process of purifying normal galectin-3 from HEK-293T cell 
supernatants. I began by optimizing an ammonium sulfate precipitation, to find at what 
percent ammonium sulfate galectin-3 precipitates relative to the bulk of protein in the 
cell supernatant. By testing multiple percentages, performing the precipitations, and 
comparing galectin-3 Western blots to total protein stains, I determined that the 30-
50% ammonium sulfate fraction is optimal (Figure 7A-B). At this concentration, the 
entirety of galectin-3 is found in the protein precipitate, while a significant amount of 
contaminating protein remains in the supernatant, as can be seen by a serial 
precipitation.  
 I followed this with various column-based purification strategies. We began by 
running the resuspended pellets from ammonium sulfate precipitation over a size 
exclusion column in an attempt to separate galectin-3 from bovine serum albumin 
(BSA), the most prevalent protein contaminant in the cell culture medium. While some 
BSA was removed during the precipitation step, a significant amount remained in the 
sample. In our initial size exclusion runs, when analyzing the collected fractions by 
galectin-3 Western blot, we saw that much of the galectin-3 came off of the size 
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Figure 7: Ammonium sulfate cuts precipitate different protein fractions from 
transfected cell supernatants for an initial purification of recombinant mouse 
galectin-3. Cell supernatant was divided into three parts and the ammonium sulfate 
concentration raised from 0 to 20, 30, or 40 percent. These fractions were centrifuged 
and supernatants were removed and raised from 20, 30, or 40 percent ammonium 
sulfate to 40, 50, or 60 percent. Centrifugation was repeated and supernatants 
removed and raised from 40, 50, or 60 percent ammonium sulfate to 80 percent in 
each. Centrifugation was repeated a final time. Precipitated protein was resuspended 
in protein buffer and diluted to normalize protein input across samples before gel runs. 
Gels were either stained for total protein or transferred for galectin-3 Western blot. Gel 
lanes shown contain protein samples made from the following ammonium sulfate cut 
pellets: 1, 0-20%; 2, 20-40%; 3, 40-80%; 4, 0-30%; 5, 30-50%; 6, 50-80%; 7, 0-40%; 
8, 40-60%; 9, 60-80%. A. Total protein stain. All protein remaining in lane 6 has been 
removed from the fraction containing galectin-3.  B. Galectin-3 Western blot. All target 
protein is present in the pellet of the 30-50% fraction (lane 5). 
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 exclusion column in the same fractions as BSA, despite the size difference of these 
two proteins (Figure 8A-B). In fact, galectin-3 was leaving the column much earlier 
than we would expect it to, based on its size. We therefore repeated the run, but 
resuspended the protein pellet in a buffer containing 20 mM lactose. The same lactose 
buffer was used to equilibrate the column. 
 With the addition of excess lactose to the buffer, we saw galectin-3 separate 
from BSA in the column fractions and elute in fractions appropriate to its size (Figure 
8C-D). This indicates that galectin-3 was associating with BSA, and that competitive 
binding with excess lactose broke the association, allowing further purification of the 
protein. All runs have therefore been performed in buffers containing 20 mM lactose 
to discourage associations with contaminating proteins.  
 Following size exclusion, we pooled the fractions containing galectin-3 as 
determined by Western blot and ran these on an anion-exchange column. Our initial 
run showed that galectin-3 binds Q resin, and that it may be eluted using a salt 
gradient (Figure 9A). We developed an optimized segmented gradient for elution that 
allowed optimal separation between galectin-3 and contaminating proteins, and 
showed a further improvement in separation (Figure 9B-C). While purification is not 
yet complete, this two-step column protocol after ammonium sulfate precipitation has 
already yielded a semi-pure suspension of galectin-3. 
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Figure 8: Purification by size exclusion chromatography requires excess 
lactose in the protein buffer to reduce binding interactions. Protein fraction 
purified by 30-50% ammonium sulfate precipitation was resuspended in protein buffer 
and run over an equilibrated size exclusion column. A. Chromatogram showing protein 
elution from the column with normal protein buffer. Boxed region shows fractions 
analyzed for total protein and galectin-3. B. Total protein stain and galectin-3 Western 
blot. Gel lanes are labeled with the number of the fraction being analyzed. The majority 
of galectin-3 is found in fractions 18, 19, and 20, which are also the main fractions 
containing BSA. C. Chromatogram showing protein elution from the column with buffer 
supplemented with 20 mM lactose. Blue boxed region shows fractions analyzed for 
total protein and galectin-3 and red boxed region shows fractions where galectin-3 
was detected. D. Total protein stain and galectin-3 Western blot with 20 mM lactose. 
Gel lanes are labeled with the number of the fraction being analyzed. The majority of 








Figure 9: Galectin-3 undergoes further purification with the use of anion-
exchange chromatography and a segmented elution gradient. Protein fractions 
from the size exclusion column were pooled and diluted with water to decrease sodium 
chloride concentration, then run over a Q resin anion-exchange column and eluted 
with a salt gradient in buffers supplemented with 20 mM lactose. A. Chromatogram 
showing protein elution from the column with a standard salt gradient. Boxed region 
shows fractions containing eluted protein. B. Chromatogram showing protein elution 
from the column with a segmented gradient. Blue boxed region shows fractions 
analyzed for total protein and galectin-3. Red boxed region shows fractions in which 
galectin-3 was detected. C. Total protein stain and galectin-3 Western blot. Galectin-







Re-stimulation of Vaccine-Primed Ex Vivo CD8+ T Cells Allows Assessment of 
Effector Function  
  To model the activation and effector response we see in our adoptively-
transferred transgenic CD8+ T cells in the NeuN mouse model of tumor tolerance, I 
utilized the ex vivo re-stimulation protocol developed in our lab (Figure 10) and 
described in Materials and Methods above.  
It was first necessary to prove that the Neu-directed tumor vaccine was 
provoking the activation and proliferation of adoptively-transferred CD8+ T cells in vivo. 
I was able to use our mock vaccine cell line to compare the Neu-directed vaccine to 
one expressing no antigen, which should not lead to proliferation and expansion of 
adoptively-transferred cells. All mice received adoptive transfer of Neu-specific CD8+ 
T cells from a transgenic donor. Mice were sorted into three treatment groups, one 
with Neu-directed vaccine, one with mock vaccine, and one with no vaccine 
administered. One mouse per group was harvested at each assessed time point after 
dosage: 24 hours, 48 hours, 4 days, and 8 days. At the 24 and 48 hour time points, 
adoptively-transferred cells were detectable in all mice, and this cell population had 
not yet undergone any cell divisions (Figure 11A). At 4 days, in mice receiving 
adoptive transfer either alone or with mock vaccine, only trace numbers of adoptively-
transferred cells were still present, and these had not undergone proliferation. In 
contrast, the cells in the mice receiving Neu vaccine had both proliferated and 
undergone several rounds of cell division (Figure 11B). At 8 days, no adoptively 
transferred cells were detectable in the mice that received transfer alone or with mock 
vaccine, but they remained present in the Neu vaccine mice, and all cells detected  
 61 
Figure 10: An ex vivo re-stimulation assay for in vitro modeling of galectin-3-
mediated suppression of CD8+ T cells. Neu antigen-specific CD8+ T cells are 
isolated from a T cell transgenic donor, labeled with proliferation dye, and adoptively 
transferred into an FVB/N recipient mouse on the same day as vaccination with a 
whole-cell irradiated Neu-expressing cell line. In vivo activation is allowed to proceed 
for 7 days. Spleen and lymph nodes are harvested for T cell isolation on day 7 and 
isolated total T cells are plated on peptide-pulsed T2-Dq cells. Galectin-3 or mutant 
protein may be added to the supernatant during a six hour in vitro re-stimulation in the 
presence of monensin. Cells are stained for surface and intracellular markers and 
analyzed by flow cytometry. 
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Figure 11: Adoptively transferred Neu-specific CD8+ T cells activate and 
proliferate in response to Neu-directed vaccine but not to mock vaccine. 
Adoptively-transferred T cells pre-stained with CFSE were harvested from FVB/N 
mice 24 hours, 48 hours, 4 days, or 8 days after vaccine, mock vaccine, or no vaccine. 
Cells were stained directly for surface markers and analyzed by flow cytometry to 
assess in vivo proliferation. A. Proliferation staining on cells isolated after 24 or 48 
hours in vivo. Adoptively-transferred cells were apparent in all three treatments and 
no proliferation had yet occurred. B. Proliferation staining on cells isolated after 4 or 8 
days in vivo. Adoptively-transferred cells only persisted in mice that received antigen-
specific vaccine. At 4 days, multiple cell divisions had occurred. By 8 days, all 






had undergone proliferation (Figure 11B). This indicates that all adoptively-
transferred cells harvested at this time point would be primed against the Neu antigen. 
 I then wanted to show that the re-stimulation of primed cells would allow us to 
assess these cells’ capability of producing effector cytokines. Using adoptively-
transferred cells harvested from mice receiving the Neu vaccine 7 days earlier, I 
performed the re-stimulation either by culturing isolated T cells alone, or at a 4:1 ratio 
with peptide-pulsed T2-Dq cells. One set of T2-Dq cells was pulsed with the Neu 
antigenic peptide P50, and the other with the control peptide NP. Indeed, T cells that 
saw their cognate peptide in culture produced easily-detectable levels of the cytokines 
interferon-gamma (IFNɣ), tumor necrosis factor alpha (TNFα), and interleukin-2 (IL-
2), while those cultured with cells holding a control peptide did not (Figure 12A-C). 
This indicates that my assay gives a successful readout of T-cell re-stimulation after 
in vivo priming, and that if galectin-3 is capable of and sufficient for CD8+ T cell 
suppression during re-stimulation, I will be able to detect it. 
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Figure 12: Re-stimulation in vitro allows detection of effector cytokines when 
stimulated with presentation of antigenic peptide but not with control peptide.  
T cells isolated after 7 days of in vivo activation and proliferation were cultured on T2-
Dq cells pulsed with either antigenic P50 or control NP peptide. After a six hour in vitro 
re-stimulation, cells were harvested and stained with fluorescent antibodies for surface 
and intracellular markers. All cells analyzed below were gated on adoptively 
transferred cells. Mean fluorescence intensity (MFI) is graphed in relative fluorescence 
units. Statistical significance was assessed using a Student’s unpaired t test with 
Welch’s correction. A. IFNɣ staining in cells stimulated on P50 or NP peptide-pulsed 
T2-Dq cells. B. TNFα staining in cells stimulated on P50 or NP peptide-pulsed T2-Dq 




Discussion and Upcoming Work 
 Our lab has shown previously that galectin-3 impairs effector functions of 
antitumor CD8+ T cells, binding directly to the cell surface and dampening the 
production of effector cytokines and granules by these cells in the tumor 
microenvironment. Removal of galectin-3 from this system results in improved 
production of effector molecules and longer-term immune control of tumor growth. 
Working off of this research, I have aimed to develop an in vitro system that will allow 
us to learn more about the mechanism of this suppressive interaction. I first attempted 
identification and characterization of protein binding partners of galectin-3 on tumor-
infiltrating CD8+ T cells, first by a lectin blot approach and then by a pull-down assay. 
When these avenues of inquiry proved unattainable with the methods and expertise I 
had available at the time, I turned to the question of how each unique binding domain 
of galectin-3 impacts its suppressive capability. 
 Using an assay modified from one our lab used previously, I have shown that 
antigen-specific CD8+ T cells activated in vivo may be successfully harvested and 
assayed for effector potential in vitro. In vivo activation occurs specifically in response 
to a vaccine for the cognate antigen, and not in the presence of mock vaccine. Re-
stimulation ex vivo successfully gives a readout of increased effector cytokine 
production in the presence of antigen-presenting cells bearing cognate peptide-MHC, 
but not with control peptide-MHC. We therefore have an established assay that will 
allow us to assess the effect of galectin-3 on the type of reactivation a CD8+ T cell 
would encounter in a tumor context, without the presence of outside factors.  
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In my upcoming work, I will be adding exogenous galectin-3 to these re-
stimulation cultures to verify the phenomenon we have seen under other experimental 
conditions, where we believe galectin-3 is binding directly to the T cell surface to 
suppress effector functions. If we see a significant decrease in the production of 
effector cytokines or components of cytotoxic granules upon the addition of purified 
recombinant galectin-3, we can be sure that suppression was not caused by 
confounding factors, and that the mechanism of suppression is likely to be mediated 
through a specific binding event at the T cell surface. Additionally, our lab already has 
the transgenic CD8+ T cell donor and FVB/N recipient mouse strains crossed to 
matched-background galectin-3 KO strains, so we will be able to test the assay in a 
galectin-3-deficient system, where the discrepancy between effector potential at 
baseline and in the presence of exogenous galectin-3 may be even more stark. We 
may then be able to assess these differences through assays that will allow us to 
determine through which cellular pathways galectin-3 is working to perform its 
suppression.  
 To make the purified recombinant galectin-3 that is essential for this assay, as 
well as its mutant forms, I used an expression vector engineered in our lab to contain 
mouse galectin-3 that would be forcibly secreted from a cell transfected with the 
vector. I engineered mutant forms of galectin-3 by performing site-directed 
mutagenesis to make a CRD point mutant, an NTD truncation mutant, and a double 
mutant. I also optimized a mammalian transfection system using HEK-293T cells in 
order to have an endotoxin-free purified protein fraction with all relevant post-
translational modifications. Upon transfection of the three mutant proteins, however, 
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we found significant problems with each. All three showed secretion defects and were 
not detected in the cell supernatant at high levels. For the truncation mutants this was 
not surprising- the N-terminal secretion sequence may have been buried within the 
folded CRD and been inaccessible. It was more surprising for the CRD point mutant, 
which displayed an entirely different pattern of expression in the transfected cell lysate 
and supernatant than normal galectin-3 did. I hypothesize that mutating the key 
Arginine residue to Glycine may have caused a defect in protein folding that altered 
the properties of the mutant protein, causing changes in binding affinities and leading 
to altered expression.  
 To attempt to remedy the secretion defects seen in the mutant proteins, I aim 
to engineer new galectin-3 mutants. For my point mutant, I will be mutating Arginine 
176 to Leucine, a branched nonpolar amino acid which may allow for less structural 
change than Glycine while also abrogating Arginine’s positively-charged side chain. 
For the truncation mutants, I plan to make new versions that retain a section of the 
galectin-3 NTD. By allowing some space between the CRD and the secretion 
sequence, I hope to see these proteins present at higher proportions in the cell 
supernatant. Once these mutagenesis steps are complete, the vectors may be tested 
in the transfection system and compared to the previous mutants and to normal 
galectin-3.  
 The purification of recombinant galectin-3 is nearing completion. By showing 
that transfection is successful in low-serum conditions, I was able to remove a large 
part of the contaminating BSA fraction before purifications begin. We have already 
optimized ammonium sulfate precipitation, size exclusion chromatography, and anion-
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exchange chromatography, and learned that using excess lactose in our running 
buffers discourages galectin-3 from undesired associations with contaminants. Our 
upcoming plan is to use this workflow followed with a cation-exchange 
chromatography step, then to begin assessments of protein purity. This will be 
achieved by loading a concentrated protein sample onto a denaturing protein gel and 
staining for total protein. We may then assess what percentage of total protein present 
in the fraction is galectin-3, and what proportion is contaminating protein. Depending 
on what contaminants remain, we will decide which column runs to repeat as part of 
our finalized workflow. Once this is complete, we will have pure mouse galectin-3 to 
use in the ex vivo CD8+ T cell re-stimulation assay. 
 While the answer to the question of how the binding properties of galectin-3 
impact its ability to suppress CD8+ T cells remains open, the development of an assay 
and appropriate reagents to test the mechanism of suppression in vitro brings us one 
step closer to learning more about this interaction. The largest remaining obstacle will 
be the purification of mutant forms of galectin-3, which may have vastly different 
properties from the normal protein. It is my opinion that this pursuit is worthwhile due 
to its potential to point us to a specific mechanism of galectin-3-mediated suppression 
of antitumor T cells. 
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CHAPTER 4: An Unexplained Link Between Galectin-3 and Antigen-Presenting 
Cells 
 
Rationale and Experimental Design 
 In our previous studies of the impact of galectin-3 on effector functions of CD8+ 
T cells, our lab also investigated other immune cell types in the normal NeuN mice 
compared to galectin-3 KO mice. As discussed in Chapter 1, previous research has 
shown mechanisms of immune suppression mediated by dendritic cell (DC) and 
plasmacytoid dendritic cell (pDC) dysfunction. Interestingly, my colleague found that 
the numbers of plasmacytoid dendritic cells (pDCs) in Lgals3-/- (galectin-3 KO) NeuN 
mice were significantly higher than in normal NeuN mice, even before the implantation 
of tumor or the administration of a treatment course. My colleague’s interpretation of 
this information was that the loss of galectin-3 causes a sharp increase in pDC 
numbers above baseline (20). I wanted to test this interpretation, and to learn more 
about its implications regarding immune modulation in the tumor microenvironment by 
galectin-3.  
 To verify what my colleague had seen, I used tumor- and treatment-naïve 
normal NeuN female mice age-matched to their galectin-3 KO counterparts. I 
harvested lymph nodes from these mice, prepared single-cell suspensions, and 
stained with fluorescent antibodies for the pDC markers Ly6C, B220, and CD11c. I 
then analyzed these cells by flow cytometry to determine whether I saw the same 
discrepancy in cell numbers. 
 Following this inquiry, I wanted to learn whether this discrepancy in pDC 
numbers is a commonality seen in many mouse strains upon abrogation of galectin-
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3. Our lab maintains breeding stocks of galectin-3 KO mice in the background strains 
FVB/N and C57Bl/6, so I performed the experiment described above comparing these 
strains to their wildtype counterparts as well. I also examined pDC numbers in 
compartments other than the lymph nodes, examining spleens and blood to see 
whether the observed increase in lymph node pDCs was actually due to a shift in 
localization of these cells from one compartment to another. 
 Finally, I wanted to learn whether other mouse models of cancer might 
demonstrate a difference in pDC numbers upon galectin-3 abrogation. For this reason, 
I compared pDC numbers at baseline in the lymph nodes of KPC and KPC-G mice to 
those I see in NeuN or galectin-3 KO NeuN mice.  
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Materials and Methods 
 
Mice 
 FVB/N background mice were purchased as needed from Jackson 
Laboratories. FVB/N Lgals3-/- (galectin-3 KO) mice were bred and backcrossed as 
previously described and bred in-house. NeuN (FVB/N-Tg(MMTVneu)202Mul/J) mice 
were originally purchased from Jackson Laboratories and bred in-house. NeuN 
galectin-3 KO mice were bred as previously described. C57Bl/6 and C57Bl/6 galectin-
3 KO mice were purchased from Jackson Laboratories and bred in-house. KPC and 
KPC-G mice were produced as described in Chapter 2. Animals were housed in the 
Johns Hopkins Animal Facility and cared for according to protocols approved by the 
Johns Hopkins Animal Care and Use Committee. 
 
Isolation of Total Cell Suspension from Spleen and Lymph Node 
 Target mice were sacrificed and spleen and/or lymph nodes dissected. Organs 
were placed into 100µM cell strainers inside of 6 well culture dishes containing 5mL 
per well of Complete RPMI (RPMI 1640, 10% FBS, 1% L-Glutamine, 0.5% penicillin-
streptomycin). To dissociate into single-cell suspension without damaging dendritic 
cell populations, spleens were first chopped into small pieces in a petri dish using a 
razor blade, then returned to the cell strainer, where the plunger of a 3mL syringe was 
used to press pieces gently against the mesh until all material but connective tissue 
had passed through. Lymph nodes were placed directly into cell strainer and gently 
pressed against the mesh until all material but connective tissue had passed through. 
Single-cell suspensions were subjected to red blood cell lysis, centrifuged, then 
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resuspended in Complete RPMI and passed through a new 100µM cell strainer to 
filter out dead material from lysis. Cells were counted, centrifuged, then resuspended 
at 1x107 cells per mL in 1X PBS for flow cytometry staining. 
 
Isolation of Non-Erythrocyte Cell Fraction from Blood 
 Large-volume blood samples were collected from target mice by clipping of the 
vena cava immediately after euthanasia. Blood was pipetted into tubes treated with 
0.5M EDTA to prevent clotting, then centrifuged. Red blood cell lysis was performed 
and cells were centrifuged, then resuspended in Complete RPMI and passed through 
a 100uM cell strainer to remove dead material from lysis. Cells were counted, then 
centrifuged and resuspended at 1x107 cells per mL in 1X PBS. 
 
Flow Cytometry 
 Cell staining began by pipetting cells into a 96-well V-bottom culture plate and 
pelleting by centrifugation. All wells to be stained for viability were then resuspended 
in 100 µL of a 1:1000 dilution of Live/Dead Aqua stain stock solution in 1X PBS. 
Staining was performed for 30 minutes at 4°C. After staining, 100 µL 1X PBS was 
added to each well before centrifugation. Cells were washed an additional two times 
with 1X PBS. 
 Each well was then resuspended in 100 µL of Mouse BD Fc Block diluted to 5 
µg per mL in 1X FACS buffer (1X PBS, 2% FBS, 2 mM EDTA) and plate was incubated 
at 4°C for 15 minutes.  
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 After incubation with Fc Block, fluorescent antibodies for surface staining were 
added directly to wells as appropriate to achieve desired dilutions. Staining was 
performed either for 20 minutes at room temperature or overnight at 4°C, protected 
from light.  
 After staining, samples were washed twice with 1X FACS buffer, then analyzed 
on a Beckman Coulter Gallios. Appropriate single stain compensation controls, 




Plasmacytoid Dendritic Cell Numbers are Lower in Normal NeuN Mice Than in 
Matched Galectin-3 KO NeuN Counterparts 
 When comparing pDC numbers in NeuN mice compared to their galectin-3 KO 
counterparts, I saw the same phenomenon described by my colleague, where pDC 
numbers were much higher in galectin-3 KO animals than in normal NeuN mice 
(Figure 13A). To elucidate this finding, I repeated the experiment to compare these 
numbers in the NeuN background strain, FVB/N. Wildtype FVB/N mice have, on 
average, the same number of pDCs in their lymph nodes as their matched galectin-3 
KO FVB/N counterparts (Figure 13B). This indicated that the difference in pDC 
numbers seen between NeuN and galectin-3 KO NeuN mice is specific only to that 
strain. I also performed the comparison in wildtype C57Bl/6 mice compared to 
galectin-3 KO counterparts, and saw a similar outcome to the FVB/N strain, where 
baseline numbers of lymph node pDCs were comparable to the numbers seen in 
galectin-3 KO NeuN mice rather than normal NeuN mice (Figure 13C). This indicates 
that it is the normal NeuN mice that have a deficiency in pDC numbers, not the NeuN 
galectin-3 KO mice that have unusually high numbers of these cells.  
 
Plasmacytoid Dendritic Cell Deficiency in NeuN Mice Does Not Extend to Other Tumor 
Models or Other Immune Cell Compartments 
 Based on our data in the NeuN mouse model of tumor tolerance, I wanted to 
learn whether the deficiency in pDC numbers in these mice could be observed in other 
mouse tumor models. I hypothesized that the loss of pDCs in the NeuN mice could be 
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Figure 13: Galectin-3 KO NeuN mice have normal pDC numbers comparable to 
wildtype and KO mice from background strains while normal NeuN mice have a 
depletion of this population. Single cell suspensions prepared from lymph nodes of 
indicated mouse strains were stained for surface markers and gated on pDC markers 
B220, Ly6C, and CD11c. A. Comparison of pDC numbers in lymph nodes of NeuN 
and NeuN galectin-3 KO mice shows a pDC deficiency in normal NeuN mice. B. 
Comparison of pDC numbers in lymph nodes of wildtype and galectin-3 KO FVB/N 
mice. C. Comparison of pDC numbers in lymph nodes of wildtype and galectin-3 KO 
C57Bl/6 mice. Only normal NeuN mice show a deficiency in pDCs, and this appears 







 due to the tolerance induced by self-tissue expression of pre-oncogenic Neu in these 
mice. Other tumor models induce tumor permissiveness through other mechanisms 
of tolerance induction, but these other mechanisms may cause a similar drop in pDC 
numbers that I would be able to detect. To this end, I prepared single-cell suspensions 
from the lymph nodes of KPC and KPC-G mice and performed staining and analysis 
by flow cytometry to compare the pDC numbers in these mice to those in the NeuN 
strain. The numbers of pDCs in KPC and KPC-G mice were very similar, and were 
comparable to the numbers observed in NeuN galectin-3 KO mice (Figure 14A). This 
outcome indicates that the difference in pDC numbers seen between NeuN and 
galectin-3 KO NeuN mice likely occurs only in that strain, and is not due to a 
mechanism of tolerance held in common between genetically engineered mouse 
tumor models.  
 I also investigated other compartments where immune cell subsets reside, to 
determine whether the decrease in pDC number in the lymph nodes of normal NeuN 
mice could be due to their migration to a different location. I compared pDCs in the 
lymph nodes, spleen, and blood of NeuN and NeuN galectin-3 KO mice, and found 
that lower pDC numbers are seen in all compartments in the NeuN mice, indicating 
that the phenomenon is not due to migration of this cell population (Figure 14B). 
 
Normal NeuN Mice Have a Deficiency in All CD11c+ Cells 
 As I investigated the differences in pDC numbers between normal and galectin-
3 deficient NeuN mice, I began to consider that this defect may not be restricted to 
pDC populations. I therefore returned to my previous data that had verified this 
 79 
Figure 14: pDC deficiency is not shared between the NeuN strain and other 
mouse strains tolerized to tumor, and is not confined to NeuN lymph nodes. A. 
Single cell suspensions from lymph nodes of KPC or KPC-G mice were stained for 
surface markers of pDCs. No difference in pDC numbers was observed between KPC 
and KPC-G mice. B. Single cell suspensions prepared from lymph nodes, spleen, and 
peripheral blood of normal NeuN or NeuN galectin-3 KO mice were stained for surface 
markers of pDCs. pDC deficiency was apparent in all compartments and is not due to 






 deficiency and examined the entire CD11c-expressing cell fraction in these two 
mouse populations. Indeed, when gating the flow cytometry data broadly by size and 
granularity, then selecting all live cells and examining the CD11c+ fraction, I found that 
the deficiency in NeuN mice extended to all CD11c+ cells, rather than being limited to 
pDCs (Figure 15). This finding could have significant implications for the use of the 
NeuN mouse model in studies of antitumor immunity. 
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Figure 15: NeuN mice are deficient in all CD11c+ cells, not only pDCs. Single cell 
suspensions prepared from lymph nodes of normal NeuN mice were stained for 
surface CD11c. Normal NeuN mice have nearly tenfold fewer CD11c+ cells than their 






 Our examination of pDC numbers in the lymph nodes of NeuN mice and their 
galectin-3 KO counterparts has revealed that the normal transgenic mice have 
significantly fewer of these cells. My colleague previously hypothesized that knockout 
of galectin-3 led to a more immune-permissive environment where more pDCs could 
proliferate and present antigen. I disproved this hypothesis by comparing pDC 
numbers in wildtype and galectin-3 KO FVB/N and C57Bl/6 mice, all of which have 
comparable pDC numbers to those seen in galectin-3 KO NeuN mice. This indicates 
that there is a deficiency in this cell type in the normal NeuN mice, not an increase in 
galectin-3 KO NeuN mice. The cause of this deficiency remains unclear. I 
hypothesized that it could be caused by mechanisms of tolerance that are shared in 
common with other genetically-engineered mouse tumor models, and that this strain 
may not be alone in seeing rescue of pDCs upon galectin-3 abrogation, but in the KPC 
mouse model there was no detectable deficiency in pDCs, indicating that this 
phenotype could truly be unique to NeuN mice.  
 In exploring this deficiency further, I showed that the decrease in pDC numbers 
in the lymph node is not caused by migration of these cells to the spleen or 
bloodstream, as all of these compartments demonstrate the deficiency to a similar 
degree when compared to galectin-3 KO NeuN mice. By re-analyzing my flow 
cytometry data, I was able to show that pDCs alone are not the sole deficient 
population; the entire CD11c+ cell fraction is depleted in these mice. Given the crucial 
role played by CD11c+ dendritic cells (DCs) in antigen presentation and the induction 
of effective immune responses, this phenomenon cannot be ignored. Any experiments 
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performed using NeuN mice should take into account that they lack significant 
numbers of a very important immune cell subset. 
 Since NeuN mice are a transgenic strain, I questioned whether the 
incorporation of the transgene could be disrupting CD11c+ cells in some way. Another 
group has determined the location of the transgene in NeuN mice, and this does not 
offer any insights into the depletion of CD11c+ cells (55). Another possibility could be 
a genetic difference left over from the process of crossing NeuN mice with galectin-3 
KO animals. NeuN galectin-3 KO mice were made backcrossing galectin-3 KO mice 
of the C57Bl/6 background with FVB/N background mice for six generations using a 
marker-assisted speed congenic approach, and were assessed as having 99.75% 
identity with the FVB/N background at the final backcross generation (20). This makes 
the presence of confounding genetic factors unlikely, but cannot be ruled out without 
performing in-depth genomic analyses of the NeuN mice compared to the NeuN 
galectin-3 KO mice.  
 One very important consideration in this finding is its implications for our 
previous data on the suppression of CD8+ T cell effector function in NeuN mice. Since 
CD11c is a marker for many DC subsets, the absence or depletion of all cells carrying 
this marker in NeuN mice could have profound impacts on CD8+ T cell effector 
function. It is possible that the suppression of CD8+ T cells in the presence of galectin-
3 is not due to a galectin-3 surface binding event, but rather to missing interactions 
between CD8+ T cells and DCs. Even if surface binding of galectin-3 to CD8+ T cells 
is involved in their suppression within the TME, a lack of CD11c+ cells could 
exacerbate this effect. 
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 If congenicity is not a factor in the observed depletion of CD11c+ cells in NeuN 
mice, abrogation of galectin-3 could truly be rescuing the depletion of an entire cell 
population. This is yet to be proven, and I have not yet been able to find a compelling 
answer in the literature for what mechanisms could be at play in such a phenomenon. 
I do, however, think it possible that there is a yet-undescribed mechanism of peripheral 
immune tolerance that involves deletion of DC populations. Peripheral tolerance 
mechanisms that target lymphocytes are well described, but similar mechanisms 
involving DCs have not been shown. I believe that such mechanisms may exist, and 
may be used by tumors as a mechanism of immune escape in certain contexts. This 
subject requires immense further study, and presently remains solely in the realm of 
conjecture. 
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CHAPTER 5: Summary 
 Recent research has cemented galectin-3 as a tumor-promoting force in the 
tumor microenvironment, as described in Chapter 1. Our lab’s past work has shown 
that mounting an immune response against galectin-3 is correlated with better patient 
outcomes after receiving a DC-stimulating tumor vaccine, and that healthy CD8+ T 
cells stimulated in vitro have better effector potential in the presence of these patients’ 
serum antibodies than without. Further work showed that galectin-3 is modulating the 
antitumor capabilities of CD8+ T cells through a mechanism that is not yet fully 
described (20). My aim has been first, to determine whether galectin-3 acts early 
enough in the development of PDAC to become a potential target for preventative 
therapeutics, and second, to develop assays that will allow us to elucidate the 
mechanisms by which galectin-3 modulates CD8+ T cell function. 
 In my studies using the KPC mouse model with and without galectin-3, we 
determined that abrogation of galectin-3 is not impacting PDAC development in a 
significant manner. While the absence of galectin-3 appeared to have a small effect 
on the duration of survival for some individuals, further analysis indicated that these 
differences may be due to sex differences rather than the presence or absence of 
galectin-3. There is no indication in the current literature that female mice or humans 
are more susceptible to galectin-3-mediated tumor promotion than males, so the 
differences we observed are likely not related to the genetic ablation of this protein. In 
the future, researchers using the KPC mouse model should take these sex-based 
survival differences into account. Taken together, these data indicate that galectin-3 
is not likely to be a top target in the development of PDAC preventative therapeutics. 
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 My other goal was to learn more about the mechanisms through which galectin-
3 modulates immune cell function in the context of tumor. Learning more about these 
mechanisms has required the development of new assays, which I hope will allow 
study of galectin-3 function and mechanism in vitro. I have optimized our lab’s ex vivo 
CD8+ T cell re-stimulation assay, and have also developed protocols for the 
purification of mouse galectin-3 from a mammalian transfection system that will as 
closely as possible match the function of galectin-3 produced at the tumor site. My 
ongoing work involves the use of this purified protein to model CD8+ T cell suppression 
in vitro. In this system, we can verify that the mechanism of this suppression is 
mediated by direct binding of galectin-3 to the T cell surface, and also use galectin-3 
mutants to determine the roles its binding domains play in these interactions.  
 Should our assay fail to show suppression of CD8+ T cells by galectin-3 in vitro 
after activation in vivo, we may instead be approaching a new model - a mechanism 
in which other cell types must be involved to achieve suppression. My colleague 
previously discovered a discrepancy in pDC numbers between NeuN mice and their 
galectin-3 KO counterparts, and I have shown that this discrepancy is actually 
extended to all CD11c+ DC subsets, and is specific to the NeuN transgenic mouse 
strain. Since this strain demonstrates heavy suppression of adoptively-transferred 
antigen-specific CD8+ T cells in the tumor microenvironment, and this effect is 
mitigated upon knockout of galectin-3, the mechanism could be an indirect one that 
requires DC involvement. Elucidating this point will require further research as there 
are no studies in the current literature that describe modulation of DCs by galectin-3 
that lead to a suppression of CD8+ T cells. 
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 Study of galectin-3 in the tumor microenvironment is complex, as this protein is 
extremely multifunctional, placing it at the interface of a multitude of intracellular and 
extracellular interactions. Elucidation of these mechanisms will require a deep grasp 
of cellular metabolic changes within the tumor microenvironment, how such changes 
affect glycosylation and other cellular processes, and how these in turn alter the 
expression, secretion, and downstream effects of galectin-3. This protein remains a 
promising target in the quest to program an immune-permissive microenvironment, 
but its targeting will be incomplete without elucidating all levels of its impact on both 
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